

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>JAK inhibitors for the treatment of... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-82/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-82" />
    
            <meta name="description" content="Read the original article in full on F1000Research: JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders" />
    
            <meta name="og:title" content="F1000Research Article: JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.">
            <meta name="og:description" content="Read the latest article version by William Vainchenker, Emilie Leroy, Laure Gilles, Caroline Marty, Isabelle Plo, Stefan N. Constantinescu, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="14282">
            <meta name="article-id" content="13167">
            <meta name="dc.title" content="JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders">
            <meta name="dc.description" content="JAK inhibitors have been developed following the discovery of the JAK2 V617F in 2005 as the driver mutation of the majority of non- BCR-ABL1 myeloproliferative neoplasms (MPNs). Subsequently, the search for JAK2 inhibitors continued with the discovery that the other driver mutations ( CALR and MPL ) also exhibited persistent JAK2 activation. Several type I ATP-competitive JAK inhibitors with different specificities were assessed in clinical trials and exhibited minimal hematologic toxicity. Interestingly, these JAK inhibitors display potent anti-inflammatory activity. Thus, JAK inhibitors targeting preferentially JAK1 and JAK3 have been developed to treat inflammation, autoimmune diseases, and graft-versus-host disease. Ten years after the beginning of clinical trials, only two drugs have been approved by the US Food and Drug Administration: one JAK2/JAK1 inhibitor (ruxolitinib) in intermediate-2 and high-risk myelofibrosis and hydroxyurea-resistant or -intolerant polycythemia vera and one JAK1/JAK3 inhibitor (tofacitinib) in methotrexate-resistant rheumatoid arthritis. The non-approved compounds exhibited many off-target effects leading to neurological and gastrointestinal toxicities, as seen in clinical trials for MPNs. Ruxolitinib is a well-tolerated drug with mostly anti-inflammatory properties. Despite a weak effect on the cause of the disease itself in MPNs, it improves the clinical state of patients and increases survival in myelofibrosis. This limited effect is related to the fact that ruxolitinib, like the other type I JAK2 inhibitors, inhibits equally mutated and wild-type JAK2 (JAK2WT) and also the JAK2 oncogenic activation. Thus, other approaches need to be developed and could be based on either (1) the development of new inhibitors specifically targeting JAK2 V617F or (2) the combination of the actual JAK2 inhibitors with other therapies, in particular with molecules targeting pathways downstream of JAK2 activation or the stability of JAK2 molecule. In contrast, the strong anti-inflammatory effects of the JAK inhibitors appear as a very promising therapeutic approach for many inflammatory and auto-immune diseases.">
            <meta name="dc.subject" content="JAK inhibitors, MPN, auto-immune diseases, inflammation, allosteric inhibitor">
            <meta name="dc.creator" content="Vainchenker, William">
            <meta name="dc.creator" content="Leroy, Emilie">
            <meta name="dc.creator" content="Gilles, Laure">
            <meta name="dc.creator" content="Marty, Caroline">
            <meta name="dc.creator" content="Plo, Isabelle">
            <meta name="dc.creator" content="Constantinescu, Stefan N.">
            <meta name="dc.date" content="2018/01/17">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.13167.1">
            <meta name="dc.source" content="F1000Research 2018 7:82">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="JAK inhibitors">
            <meta name="prism.keyword" content="MPN">
            <meta name="prism.keyword" content="auto-immune diseases">
            <meta name="prism.keyword" content="inflammation">
            <meta name="prism.keyword" content="allosteric inhibitor">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/01/17">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="82">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.13167.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-82">
            <meta name="citation_title" content="JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders">
            <meta name="citation_abstract" content="JAK inhibitors have been developed following the discovery of the JAK2 V617F in 2005 as the driver mutation of the majority of non- BCR-ABL1 myeloproliferative neoplasms (MPNs). Subsequently, the search for JAK2 inhibitors continued with the discovery that the other driver mutations ( CALR and MPL ) also exhibited persistent JAK2 activation. Several type I ATP-competitive JAK inhibitors with different specificities were assessed in clinical trials and exhibited minimal hematologic toxicity. Interestingly, these JAK inhibitors display potent anti-inflammatory activity. Thus, JAK inhibitors targeting preferentially JAK1 and JAK3 have been developed to treat inflammation, autoimmune diseases, and graft-versus-host disease. Ten years after the beginning of clinical trials, only two drugs have been approved by the US Food and Drug Administration: one JAK2/JAK1 inhibitor (ruxolitinib) in intermediate-2 and high-risk myelofibrosis and hydroxyurea-resistant or -intolerant polycythemia vera and one JAK1/JAK3 inhibitor (tofacitinib) in methotrexate-resistant rheumatoid arthritis. The non-approved compounds exhibited many off-target effects leading to neurological and gastrointestinal toxicities, as seen in clinical trials for MPNs. Ruxolitinib is a well-tolerated drug with mostly anti-inflammatory properties. Despite a weak effect on the cause of the disease itself in MPNs, it improves the clinical state of patients and increases survival in myelofibrosis. This limited effect is related to the fact that ruxolitinib, like the other type I JAK2 inhibitors, inhibits equally mutated and wild-type JAK2 (JAK2WT) and also the JAK2 oncogenic activation. Thus, other approaches need to be developed and could be based on either (1) the development of new inhibitors specifically targeting JAK2 V617F or (2) the combination of the actual JAK2 inhibitors with other therapies, in particular with molecules targeting pathways downstream of JAK2 activation or the stability of JAK2 molecule. In contrast, the strong anti-inflammatory effects of the JAK inhibitors appear as a very promising therapeutic approach for many inflammatory and auto-immune diseases.">
            <meta name="citation_description" content="JAK inhibitors have been developed following the discovery of the JAK2 V617F in 2005 as the driver mutation of the majority of non- BCR-ABL1 myeloproliferative neoplasms (MPNs). Subsequently, the search for JAK2 inhibitors continued with the discovery that the other driver mutations ( CALR and MPL ) also exhibited persistent JAK2 activation. Several type I ATP-competitive JAK inhibitors with different specificities were assessed in clinical trials and exhibited minimal hematologic toxicity. Interestingly, these JAK inhibitors display potent anti-inflammatory activity. Thus, JAK inhibitors targeting preferentially JAK1 and JAK3 have been developed to treat inflammation, autoimmune diseases, and graft-versus-host disease. Ten years after the beginning of clinical trials, only two drugs have been approved by the US Food and Drug Administration: one JAK2/JAK1 inhibitor (ruxolitinib) in intermediate-2 and high-risk myelofibrosis and hydroxyurea-resistant or -intolerant polycythemia vera and one JAK1/JAK3 inhibitor (tofacitinib) in methotrexate-resistant rheumatoid arthritis. The non-approved compounds exhibited many off-target effects leading to neurological and gastrointestinal toxicities, as seen in clinical trials for MPNs. Ruxolitinib is a well-tolerated drug with mostly anti-inflammatory properties. Despite a weak effect on the cause of the disease itself in MPNs, it improves the clinical state of patients and increases survival in myelofibrosis. This limited effect is related to the fact that ruxolitinib, like the other type I JAK2 inhibitors, inhibits equally mutated and wild-type JAK2 (JAK2WT) and also the JAK2 oncogenic activation. Thus, other approaches need to be developed and could be based on either (1) the development of new inhibitors specifically targeting JAK2 V617F or (2) the combination of the actual JAK2 inhibitors with other therapies, in particular with molecules targeting pathways downstream of JAK2 activation or the stability of JAK2 molecule. In contrast, the strong anti-inflammatory effects of the JAK inhibitors appear as a very promising therapeutic approach for many inflammatory and auto-immune diseases.">
            <meta name="citation_keywords" content="JAK inhibitors, MPN, auto-immune diseases, inflammation, allosteric inhibitor">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="William Vainchenker">
            <meta name="citation_author_institution" content="UMR 1170, Gustave Roussy, Villejuif, France">
            <meta name="citation_author_institution" content="Universit&eacute; Paris-Saclay, UMR1170, Gustave Roussy, Villejuif, France">
            <meta name="citation_author_institution" content="INSERM UMR 1170, Gustave Roussy, Villejuif, France">
            <meta name="citation_author" content="Emilie Leroy">
            <meta name="citation_author_institution" content="Signal Transduction &amp; Molecular Hematology Unit, Ludwig Institute for Cancer Research, Brussels, Belgium">
            <meta name="citation_author_institution" content="de Duve Institute, Universit&eacute; catholique de Louvain, Brussels, Belgium">
            <meta name="citation_author" content="Laure Gilles">
            <meta name="citation_author_institution" content="Institut National de la Transfusion Sanguine, Paris, France">
            <meta name="citation_author" content="Caroline Marty">
            <meta name="citation_author_institution" content="UMR 1170, Gustave Roussy, Villejuif, France">
            <meta name="citation_author_institution" content="Universit&eacute; Paris-Saclay, UMR1170, Gustave Roussy, Villejuif, France">
            <meta name="citation_author_institution" content="INSERM UMR 1170, Gustave Roussy, Villejuif, France">
            <meta name="citation_author" content="Isabelle Plo">
            <meta name="citation_author_institution" content="UMR 1170, Gustave Roussy, Villejuif, France">
            <meta name="citation_author_institution" content="Universit&eacute; Paris-Saclay, UMR1170, Gustave Roussy, Villejuif, France">
            <meta name="citation_author_institution" content="INSERM UMR 1170, Gustave Roussy, Villejuif, France">
            <meta name="citation_author" content="Stefan N. Constantinescu">
            <meta name="citation_author_institution" content="Signal Transduction &amp; Molecular Hematology Unit, Ludwig Institute for Cancer Research, Brussels, Belgium">
            <meta name="citation_author_institution" content="de Duve Institute, Universit&eacute; catholique de Louvain, Brussels, Belgium">
            <meta name="citation_publication_date" content="2018/01/17">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="82">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.13167.1">
            <meta name="citation_firstpage" content="82">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-82/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-82.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=14282 /> <input type=hidden id=articleId name=articleId value=13167 /> <input type=hidden id=xmlUrl value="/articles/7-82/v1/xml"/> <input type=hidden id=xmlFileName value="-7-82-v1.xml"> <input type=hidden id=article_uuid value=1e9edc68-e339-46e0-83ab-1355fe0b3138 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.13167.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.13167.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-82"
  },
  "headline": "JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders",
  "datePublished": "2018-01-17T16:33:16",
  "dateModified": "2018-01-17T16:33:16",
  "author": [
    {
      "@type": "Person",
      "name": "William Vainchenker"
    },    {
      "@type": "Person",
      "name": "Emilie Leroy"
    },    {
      "@type": "Person",
      "name": "Laure Gilles"
    },    {
      "@type": "Person",
      "name": "Caroline Marty"
    },    {
      "@type": "Person",
      "name": "Isabelle Plo"
    },    {
      "@type": "Person",
      "name": "Stefan N. Constantinescu"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as the driver mutation of the majority of non-BCR-ABL1 myeloproliferative neoplasms (MPNs). Subsequently, the search for JAK2 inhibitors continued with the discovery that the other driver mutations (CALR and MPL) also exhibited persistent JAK2 activation. Several type I ATP-competitive JAK inhibitors with different specificities were assessed in clinical trials and exhibited minimal hematologic toxicity. Interestingly, these JAK inhibitors display potent anti-inflammatory activity. Thus, JAK inhibitors targeting preferentially JAK1 and JAK3 have been developed to treat inflammation, autoimmune diseases, and graft-versus-host disease. Ten years after the beginning of clinical trials, only two drugs have been approved by the US Food and Drug Administration: one JAK2/JAK1 inhibitor (ruxolitinib) in intermediate-2 and high-risk myelofibrosis and hydroxyurea-resistant or -intolerant polycythemia vera and one JAK1/JAK3 inhibitor (tofacitinib) in methotrexate-resistant rheumatoid arthritis. The non-approved compounds exhibited many off-target effects leading to neurological and gastrointestinal toxicities, as seen in clinical trials for MPNs. Ruxolitinib is a well-tolerated drug with mostly anti-inflammatory properties. Despite a weak effect on the cause of the disease itself in MPNs, it improves the clinical state of patients and increases survival in myelofibrosis. This limited effect is related to the fact that ruxolitinib, like the other type I JAK2 inhibitors, inhibits equally mutated and wild-type JAK2 (JAK2WT) and also the JAK2 oncogenic activation. Thus, other approaches need to be developed and could be based on either (1) the development of new inhibitors specifically targeting JAK2V617F or (2) the combination of the actual JAK2 inhibitors with other therapies, in particular with molecules targeting pathways downstream of JAK2 activation or the stability of JAK2 molecule. In contrast, the strong anti-inflammatory effects of the JAK inhibitors appear as a very promising therapeutic approach for many inflammatory and auto-immune diseases."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-82/v1",
            "name": "JAK inhibitors for the treatment of myeloproliferative neoplasms and..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> JAK inhibitors for the treatment of myeloproliferative neoplasms and... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=14282 data-id=13167 data-downloads="" data-views="" data-scholar="10.12688/f1000research.13167.1" data-recommended="" data-doi="10.12688/f1000research.13167.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-82/v1/pdf?article_uuid=1e9edc68-e339-46e0-83ab-1355fe0b3138" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-13167-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-13167-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-13167-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Vainchenker W, Leroy E, Gilles L <em>et al.</em> JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):82 (<a class=new-orange href="https://doi.org/10.12688/f1000research.13167.1" target=_blank>https://doi.org/10.12688/f1000research.13167.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-13167-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=13167 id=track-article-signin-13167 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/13167?target=/articles/7-82/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=14282 /> <input name=articleId type=hidden value=13167 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:verpre@igr.fr" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>William Vainchenker</span></a><a href="https://orcid.org/0000-0003-4705-202X" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-4705-202X</div><sup>1-3</sup>,&nbsp;</span><span class="">Emilie Leroy<sup>4,5</sup>,&nbsp;</span><span class="">Laure Gilles<sup>6</sup>,&nbsp;</span><span class="">Caroline Marty<sup>1-3</sup>,&nbsp;</span><span class="">Isabelle Plo<sup>1-3</sup>,&nbsp;</span><span class="">Stefan N. Constantinescu<sup>4,5</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:verpre@igr.fr" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>William Vainchenker</span></a><a href="http://orcid.org/0000-0003-4705-202X" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-4705-202X</div><sup>1-3</sup>,&nbsp;</span><span class="">Emilie Leroy<sup>4,5</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Laure Gilles<sup>6</sup>,&nbsp;</span><span class=article-page-hidden-authors>Caroline Marty<sup>1-3</sup>,&nbsp;</span><span class="">Isabelle Plo<sup>1-3</sup>,&nbsp;</span><span class="">Stefan N. Constantinescu<sup>4,5</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 17 Jan 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.13167.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> INSERM UMR 1170, Gustave Roussy, Villejuif, France<br/> <sup>2</sup> Universit&eacute; Paris-Saclay, UMR1170, Gustave Roussy, Villejuif, France<br/> <sup>3</sup> UMR 1170, Gustave Roussy, Villejuif, France<br/> <sup>4</sup> Signal Transduction &amp; Molecular Hematology Unit, Ludwig Institute for Cancer Research, Brussels, Belgium<br/> <sup>5</sup> de Duve Institute, Universit&eacute; catholique de Louvain, Brussels, Belgium<br/> <sup>6</sup> Institut National de la Transfusion Sanguine, Paris, France<br/> <p> <div class=margin-bottom> William Vainchenker <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Emilie Leroy <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Laure Gilles <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Caroline Marty <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Isabelle Plo <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Stefan N. Constantinescu <br/> <span>Roles: </span> Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=8359-29676></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=29675-29677></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> JAK inhibitors have been developed following the discovery of the <i>JAK2</i>V617F in 2005 as the driver mutation of the majority of non-<i>BCR-ABL1 </i>myeloproliferative neoplasms (MPNs). Subsequently, the search for JAK2 inhibitors continued with the discovery that the other driver mutations (<i>CALR</i> and <i>MPL</i>) also exhibited persistent JAK2 activation. Several type I ATP-competitive JAK inhibitors with different specificities were assessed in clinical trials and exhibited minimal hematologic toxicity. Interestingly, these JAK inhibitors display potent anti-inflammatory activity. Thus, JAK inhibitors targeting preferentially JAK1 and JAK3 have been developed to treat inflammation, autoimmune diseases, and graft-versus-host disease. Ten years after the beginning of clinical trials, only two drugs have been approved by the US Food and Drug Administration: one JAK2/JAK1 inhibitor (ruxolitinib) in intermediate-2 and high-risk myelofibrosis and hydroxyurea-resistant or -intolerant polycythemia vera and one JAK1/JAK3 inhibitor (tofacitinib) in methotrexate-resistant rheumatoid arthritis. The non-approved compounds exhibited many off-target effects leading to neurological and gastrointestinal toxicities, as seen in clinical trials for MPNs. Ruxolitinib is a well-tolerated drug with mostly anti-inflammatory properties. Despite a weak effect on the cause of the disease itself in MPNs, it improves the clinical state of patients and increases survival in myelofibrosis. This limited effect is related to the fact that ruxolitinib, like the other type I JAK2 inhibitors, inhibits equally mutated and wild-type JAK2 (JAK2WT) and also the JAK2 oncogenic activation. Thus, other approaches need to be developed and could be based on either (1) the development of new inhibitors specifically targeting <i>JAK2</i>V617F or (2) the combination of the actual JAK2 inhibitors with other therapies, in particular with molecules targeting pathways downstream of JAK2 activation or the stability of JAK2 molecule. In contrast, the strong anti-inflammatory effects of the JAK inhibitors appear as a very promising therapeutic approach for many inflammatory and auto-immune diseases. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> JAK inhibitors, MPN, auto-immune diseases, inflammation, allosteric inhibitor </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> William Vainchenker (<a href="mailto:verpre@igr.fr">verpre@igr.fr</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> William Vainchenker </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported by grants from Ligue Nationale Contre le Cancer (‘Equipe labellisée 2016’ to WV and IP), Institut National du Cancer (PLBIO2015 to IP), MPN Research Foundation (IP), and Institut National de la Santé et de la Recherche Médicale (Inserm). The Laboratory of Excellence Globule Rouge-Excellence (IP and WV) is funded by the program ‘Investissements d’avenir’. SNC has received funding from the Ludwig Institute for Cancer Research, FRS-FNRS, Salus Sanguinis, Fondation contre le cancer, Project Action de Recherche Concerte of the Université Catholique de Louvain ARC10/15-027, the PAI (Interuniversity Support Program) Belgian Medical Genetics Initiative, and the Foundation ‘Les avions de Sébastien’ (Belgium). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Vainchenker W <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Vainchenker W, Leroy E, Gilles L <em>et al.</em> JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):82 (<a href="https://doi.org/10.12688/f1000research.13167.1" target=_blank>https://doi.org/10.12688/f1000research.13167.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 17 Jan 2018, <b>7</b>(F1000 Faculty Rev):82 (<a href="https://doi.org/10.12688/f1000research.13167.1" target=_blank>https://doi.org/10.12688/f1000research.13167.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 17 Jan 2018, <b>7</b>(F1000 Faculty Rev):82 (<a href="https://doi.org/10.12688/f1000research.13167.1" target=_blank>https://doi.org/10.12688/f1000research.13167.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d88552e287>Introduction</h2><p class="" id=d88552e290>Janus kinases (JAKs) play a central role in the regulation of hematopoiesis as being mandatory for signaling by receptors for hematopoietic/immunological cytokines<sup><a href="#ref-1">1</a></sup>. They control survival, proliferation, and differentiation of hematopoietic cells as well as the function of mature cells by binding to hematopoietic type I and type II cytokine receptors, which are devoid of catalytic activity (<a href="#f1">Figure 1</a>). JAKs pre-associated to these receptors to form a functional signaling complex<sup><a href="#ref-1">1</a></sup>. Cytokine binding induces or re-orients receptor dimerization, such that JAK kinase domains face each other in a productive conformation for transactivation and phosphorylation of the cytokine receptor cytoplasmic tails<sup><a href="#ref-1">1</a></sup>. The latter and JAKs themselves become scaffolds for signaling molecules, particularly for the members of the signal transducer and activator of transcription (STAT) family, which in turn are phosphorylated and homo/hetero-dimerize before translocating to the nucleus. JAK activation also initiates activation of mitogen-activated protein kinase (MAPK), phosphatidylinositol-3′-kinase (PI3K), and AKT/mammalian target of rapamycin (mTOR) (<a href="#f2">Figure 2</a>)<sup><a href="#ref-2">2</a></sup>.</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/14282/a6b7053e-1d6f-49e9-8144-1be91b87572d_figure1.gif"><img alt="a6b7053e-1d6f-49e9-8144-1be91b87572d_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/14282/a6b7053e-1d6f-49e9-8144-1be91b87572d_figure1.gif"></a><div class=caption><h3>Figure 1. Janus kinases (JAKs) and the cytokine receptor superfamily.</h3><p id=d88552e326>Schematic representation of type I and type II cytokine receptor subfamilies based on the extracellular domain sequence homologies. The different JAKs (JAK1, JAK2, JAK3, and TYK2) are employed by each class of receptors, as indicated. Type I receptors can form homodimers (α/α), heterodimers (α/β), or oligomers (gp130/α/gp130);(α/β/γ), although the α chain is mainly responsible for cytokine binding. Cytokine receptor complexes composed of two or more different chains activate at least two different JAKs, while single-chain receptors such as homodimeric receptors activate JAK2 only (although TpoR/MPL and G-CSFR/CSF3R can also use TYK2 and JAK1, respectively). The myelopoiesis-related cytokine receptors are denoted in red, and the lymphopoiesis-related cytokines receptors are denoted in green.</p></div></div><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/14282/a6b7053e-1d6f-49e9-8144-1be91b87572d_figure2.gif"><img alt="a6b7053e-1d6f-49e9-8144-1be91b87572d_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/14282/a6b7053e-1d6f-49e9-8144-1be91b87572d_figure2.gif"></a><div class=caption><h3>Figure 2. Principal signaling pathways activated by homodimeric cytokine receptors.</h3><p id=d88552e343>Cytokine binding to the extracellular domain of receptors induces conformation changes that enable cross-phosphorylation of the appended Janus kinases (JAKs), which then can activate each other. As a result, JAK molecules phosphorylate tyrosine residues on the intracellular part of the receptor, which then can serve as docking sites for SH2 domain containing signaling molecules such as signal transducer and activator of transcription (STAT) but also proteins from the phosphatidylinositol-3′-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways.</p></div></div><p class="" id=d88552e350>The JAK/STAT pathway is frequently dysregulated in malignant diseases and in disorders with an abnormal immunological response<sup><a href="#ref-3">3</a></sup>.</p><p class="" id=d88552e358>The discovery that classic <i>BCR-ABL1</i>–negative myeloproliferative neoplasms (MPNs) are constantly associated with abnormal JAK2 activation due to different mutations, has paved the way for the development of JAK inhibitors in the therapy of these disorders as well as of other diseases with either genetic alterations in the JAK pathway or JAK-induced activation by autocrine and paracrine cytokine loops<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>. Here, we focus on the role of JAKs as potential therapeutic targets, the development of JAK inhibitors and their limitations, and potential new strategies targeting the JAKs.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d88552e374>Janus kinases</h2><p class="" id=d88552e377>The human genome codes for four JAKs: JAK1, JAK2, JAK3, and TYK2<sup><a href="#ref-1">1</a></sup>. Like the god Janus, who has two faces and opens doors, JAKs possess two kinase domains—one catalytically active domain at the C-terminus and an upstream pseudokinase domain that binds ATP—but does not phosphorylate substrates (except weakly itself). At the N-terminus, JAKs possess a FERM (band four-point-one, ezrin, radixin, moesin)-like domain and an Src homology 2 (SH2)-like domain (<a href="#f3">Figure 3A</a>). The non-covalent attachment of JAKs to cytokine receptor tails is specific and depends on the FERM domain and on the juxtamembrane receptor sequence containing a proline-rich Box 1 and a motif denoted Box 2 with both hydrophobic and negatively charged residues as well as the sequences stretching from Box 1 to Box 2<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>. JAK2 associates with the three homodimeric receptors: erythropoietin receptor (EPOR), thrombopoietin receptor (MPL/TPOR), and the granulocyte colony-stimulating factor receptor (G-CSFR/CSF3R). JAK1, JAK2, and TYK2 can also associate with heterodimeric or trimeric receptors, and JAK3 only with receptors containing the γ-chain with solely JAK1 as partner (<a href="#f1">Figure 1</a>)<sup><a href="#ref-1">1</a></sup>. The precise structure of receptor/JAK complexes remains unknown. Recently, the structures of the kinase and pseudokinase domains of JAK1, JAK2, and TYK2 were obtained and represent a major asset for the identification of novel (allosteric) inhibitors (see below)<sup><a href="#ref-8">8</a>–<a href="#ref-10">10</a></sup>. Interestingly, JAKs also play a role of chaperones for traffic and stability at the cell surface of several cytokine receptors<sup><a href="#ref-11">11</a></sup>.</p><div class="fig panel clearfix"><a name=f3 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/14282/a6b7053e-1d6f-49e9-8144-1be91b87572d_figure3.gif"><img alt="a6b7053e-1d6f-49e9-8144-1be91b87572d_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/14282/a6b7053e-1d6f-49e9-8144-1be91b87572d_figure3.gif"></a><div class=caption><h3>Figure 3. The kinase domain of Janus kinase 2 (JAK2) has been commonly targeted by the current inhibitors.</h3><p id=d88552e423>(<b>A</b>) Secondary structure of JAK molecules. They are composed (from the N- to C-terminal end) of a FERM domain (band 4.1, erzin, radixin, moeisin domain), a pseudo-SH2 domain (ψ-SH2), a pseudokinase domain (JH2), and a kinase domain (JH1). While the major function of the N-terminus region is to specifically bind to cytokine receptor intracellular tail, the carboxyl-terminal region contains the catalytically active kinase domain, JH1, and the regulatory domain, JH2, of which the exact function is still matter of debate. (<b>B</b>) Three-dimensional representation of JAK2 kinase domain in its active conformation (PDB: 3KRR<sup><a href="#ref-12">12</a></sup>) bound to type 1 inhibitor, ruxolitinib (show in yellow spheres). The binding of ruxolitinib has been modelled on the basis of the co-crystal of ruxolitinib-bound Scr (PDB: 4U5J<sup><a href="#ref-13">13</a></sup>). The activation loop, colored in pink, adopts an ‘open’ (active) conformation stabilized by phosphorylation of tyrosine residues 1007 and 1008. The αC is colored in orange. (<b>C</b>) Three-dimensional representation of JAK2 kinase domain in its inactive conformation bound to a type 2 inhibitor, NVP-BTT594 (PDB: 3UGC<sup><a href="#ref-14">14</a></sup>). The activation loop, colored in pink, adopts a ‘closed’ (inactive) conformation. The compound is shown in cyan spheres, and the αC in orange. (D) Illustration of the structures of the main compounds discussed in this review.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d88552e455>Disease associated with abnormal JAK activation</h2><p class="" id=d88552e458>Autonomous activation of the JAK/STAT pathway is central in several pathologies. Genetic alterations targeting this signaling pathway are associated mainly with hematologic malignancies. Pathological JAK activation also occurs in diseases linked to abnormal cytokine stimulation.</p><div class=section><a name=d88552e461 class=n-a></a><h3 class=section-title>Hematologic malignancies</h3><p class="" id=d88552e466>In many myeloid and lymphoid malignancies, driver mutations leading to constitutive JAK activation can be found. The paradigm is represented by <i>BCR-ABL1</i>–negative MPNs as they are all related to mutations activating JAK2, which in more than 50% of the cases both initiate and drive the disease phenotype. Thus, the development of JAK2 inhibitors is particularly critical for MPNs.</p><p class="" id=d88552e472><b><i>Classic <i>BCR-ABL1</i>–negative MPNs.</i></b> The classic <i>BCR-ABL1</i>–negative MPNs (hereafter, MPNs) include three different disorders—essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF)—and are caused by constitutive activation of the cytokine receptor/JAK2 pathway due to acquired somatic mutations in three major genes<sup><a href="#ref-15">15</a></sup>. <i>JAK2</i>V617F is the most prevalent mutation in MPNs associated with the three disorders (65–70%) and is present in 95% of PVs. Mutations in the exon 12 of <i>JAK2</i> are found in around 2% of PV, which are negative for the <i>JAK2</i>V617F mutation (reviewed in <a href="#ref-15">15</a>). Interestingly, these two <i>JAK2</i>-activating mutations are not located in the kinase domain of the protein but involve amino acid changes in the pseudokinase (JH2) domain (<i>JAK2</i>V617F) and the SH2-JH2 linker domain (<i>JAK2 exon 12</i>) (<a href="#f3">Figure 3A</a> and see below). Mutations in the thrombopoietin receptor (<i>MPL</i>) gene are much rarer than <i>JAK2</i> mutations and are present in 3% of MPNs (4–5% of ET and myelofibrosis [MF]). The recurrent mutations are located in the exon 10. The most frequent are substitutions of the W515 residue to many other amino acids, mostly L or K but also R or A (reviewed in <a href="#ref-15">15</a>). In MPNs, the <i>MPL</i>S505N mutation is also found but less frequently than in hereditary thrombocytosis. Rarer mutations of <i>MPL</i> have been described in both the extracellular and intracellular domains. The third gene found frequently mutated in MPNs is calreticulin<i></i> (<i>CALR</i>), which is affected by mutations leading to a +1 frameshift in the exon 9<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>. As for <i>MPL</i>, <i>CALR</i> mutations are associated with ET and MF but with a higher frequency (25%). CALR is not a molecule directly involved in activation of JAK2, but the new C-terminus common to all mutants allows the CALR mutants to tightly bind and activate MPL and JAK2<sup><a href="#ref-18">18</a>–<a href="#ref-21">21</a></sup>.</p><p class="" id=d88552e555>All of these activating mutations mimic the effects of hematopoietic cytokines by inducing constitutive signaling via the STAT, PI3K, and ERK/MAPK pathways. To achieve this, <i>JAK2</i>V617F must be bound to cytokine receptors, more particularly homodimeric receptors (EPOR, CSF3R/G-CSFR, and MPL/TPOR), which allow its dimerization and activation<sup><a href="#ref-22">22</a></sup>. CALR mutants specifically activate MPL and (to a lesser extent) G-CSFR, and <i>MPL</i> mutations result in an active conformation of the receptor<sup><a href="#ref-18">18</a></sup>. Loss-of-function mutations in <i>SH2B3</i>, a negative regulator of JAK2, have been described as drivers in MPNs and idiopathic erythrocytosis<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>, but there is evidence that in the majority of the cases it is either a secondary mutation or a germ-line mutation predisposing to MPNs<sup><a href="#ref-25">25</a></sup>.</p><p class="" id=d88552e587>In 20–30% of patients with MPNs, mutations besides driver JAK2-activating mutations have been identified in genes involved in splicing (<i>SRSF2</i> and <i>U2AF1</i>) and epigenetic regulation (<i>TET2</i>, <i>DNMT3A</i>, <i>ASXL1</i>, <i>EZH2</i>, and <i>IDH1/IDH2</i>) and in tumor suppressor genes (<i>TP53</i>)<sup><a href="#ref-15">15</a>,<a href="#ref-26">26</a>,<a href="#ref-27">27</a></sup>. They could predate or follow the driver mutations<sup><a href="#ref-28">28</a>–<a href="#ref-30">30</a></sup>. Mutations, such as in <i>TET2</i>, <i>DNMT3A</i>, or <i>EZH2</i>, favor clonal dominance and disease initiation<sup><a href="#ref-28">28</a>,<a href="#ref-31">31</a></sup>. Of note, these associated mutations promote progression to MF or leukemic transformation (<i>ASXL1</i>, <i>IDH1/2</i>, <i>EZH2</i>, and <i>TP53</i>)<sup><a href="#ref-32">32</a>,<a href="#ref-33">33</a></sup>. Almost always, one such mutation is present in PMF, and the number of such mutations correlates with the severity of the disease<sup><a href="#ref-32">32</a>,<a href="#ref-33">33</a></sup> and might modulate the response to JAK2 inhibition.</p><p class="" id=d88552e677><b><i>Other myeloid malignancies</i></b></p><p class="" id=d88552e682><b>MPN associated with JAK2 fusion proteins</b></p><p class="" id=d88552e686>Four fusion proteins—ETV6 (TEL)-JAK2 (t(9;12) (p24;p13), PCM1-JAK2 (t(8;9) (p22;p24), BCR-JAK2 (t(9;22) (p24;q11.2), and RPN1-JAK2 (t(3;9) (q21;p24)—have been described in some MPNs—PMF, chronic eosinophilic leukemia (CEL), atypical chronic myeloid leukemia (aCML), and unclassified MPNs—or in mixed MPN/myelodysplastic syndrome (MPN/MDS)<sup><a href="#ref-34">34</a>–<a href="#ref-37">37</a></sup>. The translocation partner of JAK2 sets the expression level and induces dimerization of JAK2 kinase domains.</p><p class="" id=d88552e696><b>Chronic neutrophilic leukemia, an MPN associated with G-CSFR (</b><i>CSFR3</i><b>) mutations</b></p><p class="" id=d88552e704>Acquired activating <i>CSF3R</i> mutations have been found in the great majority of chronic neutrophilic leukemias (CNLs). Most CNLs carry a T618I mutation (T595I if the first counted residue is after the peptide signal sequence)<sup><a href="#ref-38">38</a></sup>. The T615N (T592N) mutation has also been described but more rarely. <i>CSF3R</i> mutations have also initially been described in aCML but are much less frequent than in CNL.</p><p class="" id=d88552e717><i>JAK2</i>V617F and (to a lower extent) <i>MPL</i> and <i>CALR</i> mutations are extremely prevalent in refractory anemia with ring sideroblasts and thrombocytosis and are associated with <i>SF3B1</i> mutations<sup><a href="#ref-39">39</a></sup>.</p><p class="" id=d88552e736>Mutations in <i>JAK2</i> or cytokine receptors are rare in the other myeloid malignancies. They can be found in chronic myelomonocytic leukemia (CMML) but always associated with other mutations.</p><p class="" id=d88552e742>In acute myeloid leukemia (AML), mutations in <i>JAKs</i> are rare and, when present, mostly involve <i>JAK1</i>. <i>CSF3R</i> mutations have also been described but as late events. The only AML associated frequently with <i>JAK</i> mutations is Down syndrome acute megakaryoblastic leukemia (AMKL), where <i>JAK1</i>, <i>JAK2</i>, and also <i>JAK3</i> mutations are found in around 20% of cases<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup>.</p><p class="" id=d88552e774>In acute myeloid leukemia (AML), mutations in <i>JAKs</i> are rare and, when present, mostly involve <i>JAK1</i>. <i>CSF3R</i> mutations have also been described but as late events. The only AML associated frequently with <i>JAK</i> mutations is Down syndrome acute megakaryoblastic leukemia (AMKL), where <i>JAK1</i>, <i>JAK2</i>, and also <i>JAK3</i> mutations are found in around 20% of cases<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup>.</p><p class="" id=d88552e806><b><i>Lymphoid malignancies.</i></b> JAK2 activation may play a more significant role in the pathogenesis of B and T neoplasms than previously thought, although they might be only secondary events. JAK/STAT activation occurs via either mutations/translocations or cytokine paracrine/autocrine loops.</p><p class="" id=d88552e812><b>Acute lymphoblastic leukemia</b></p><p class="" id=d88552e816>In B-cell acute lymphoblastic leukemia (B-ALL), a new subtype has emerged called <i>BCR-ABL1</i>-like subtype (15% of pediatric ALL and 50% of ALL with Down syndrome), as it exhibits a transcriptional profile similar to that of <i>BCR-ABL1</i><b>–</b>positive ALL with poor prognosis<sup><a href="#ref-42">42</a></sup>. Half of them have <i>JAK1</i> and <i>JAK2</i> mutations and rearrangement of <i>CRLF2</i>, a gene encoding a cytokine receptor<sup><a href="#ref-43">43</a>,<a href="#ref-44">44</a></sup>. The most frequent <i>JAK2</i> mutations target the R683 (R683G/S), a residue present in the DIREED motif located in the hinge between the N- and C-lobes of the pseudokinase domain of JAK2<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>. Fusion with partners ETV6, BCR, PAX, and SSBP2 results in the activation of JAK2 kinase domain. Mutations in <i>JAK1</i> are relatively rare in B-ALL in comparison with T-cell ALL (T-ALL)<sup><a href="#ref-46">46</a></sup> and are located in the FERM domain and the pseudokinase domain. For instance, <i>JAK1</i>V658F is the equivalent of <i>JAK2</i>V617F<sup><a href="#ref-47">47</a></sup>. In most cases, <i>JAK2</i> mutations are associated with an aberrant expression of CRLF2, a cytokine receptor chain which associates with IL-7RA to bind the thymic stromal lymphopoietin (TSLP)<sup><a href="#ref-48">48</a></sup>. The F232C-activating mutation in <i>CRLF2</i> induces homodimerization of CRLF2 and is detected in 10% of cases overexpressing CRLF2<sup><a href="#ref-49">49</a></sup>. Activating mutations in the <i>IL-7RA</i> have been described either as point mutation (S185C) or as an insertion-deletion in the transmembrane domain inducing homodimerization of the IL-7RA<sup><a href="#ref-50">50</a></sup>. Truncating rearrangements of the <i>EPOR</i> have also been identified<sup><a href="#ref-51">51</a></sup>.</p><p class="" id=d88552e906>In T-ALL, mutations in <i>JAK1</i>, <i>JAK2</i>, <i>JAK3</i>, and the <i>IL-7R</i> are found in around 15% of cases, more particularly in early T-cell progenitor (ETP)-ALL<sup><a href="#ref-52">52</a></sup>. Targeting JAKs in these two types of ALL appears to be a valuable approach.</p><p class="" id=d88552e925><b>Hodgkin lymphoma and primary mediastinal B-cell lymphoma</b></p><p class="" id=d88552e929>Hodgkin lymphoma and primary mediastinal B-cell lymphoma (PMBL) have some common mechanisms of lymphomagenesis, being driven by alterations in the nuclear factor-kappa B (NFκB) and JAK/STAT pathways<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup>. In rare cases (3%), a JAK2 fusion protein (SEC31A-JAK2) is present<sup><a href="#ref-55">55</a></sup>.</p><p class="" id=d88552e943><b>Other lymphoma</b></p><p class="" id=d88552e947>In T-cell pro-lymphocytic leukemia, mutations in <i>JAK1</i> (8%) and <i>JAK3</i> (30%) (more particularly M511I) have been described<sup><a href="#ref-56">56</a></sup>. <i>JAK3</i> mutations (particularly A572V and A573V) are frequent (35%) in natural killer/T-cell lymphomas<sup><a href="#ref-57">57</a></sup>. Mutations or silencing of negative regulators of JAKs (<i>PTPN2</i> and <i>SOCS1</i>) is also frequent in diffuse large B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma.</p><p class="" id=d88552e974>An autocrine/paracrine cytokine loop induced by IL-6, IL-10, and IL-13 activates JAKs. This occurs in several types of lymphoma as well as in chronic lymphocytic leukemia and Waldenström macroglobulinemia<sup><a href="#ref-58">58</a></sup>.</p></div><div class=section><a name=d88552e982 class=n-a></a><h3 class=section-title>Disorders other than hematologic malignancies</h3><p class="" id=d88552e987><b><i>Inherited disorders of the hematopoietic system.</i></b> The majority of inherited thrombocytosis are related to spontaneous activation of the MPL/JAK2 pathways due to <i>MPL</i> or <i>JAK2</i> mutations<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>. The other mechanism is related to an excess of plasma thrombopoietin (TPO) due either to an excessive synthesis or to a defect in its clearance as a consequence of <i>MPL</i> mutations affecting receptor trafficking. This excess of TPO induces JAK2 activation<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>.</p><p class="" id=d88552e1016>Inherited erythrocytosis are related to excess erythropoietin (EPO) synthesis or to gain-of-function mutations in <i>EPOR</i> that activate JAK2<sup><a href="#ref-60">60</a></sup>. Hereditary neutrophilia carry activating mutations of <i>CSF3R</i> that activate JAK2<sup><a href="#ref-61">61</a></sup>.</p><p class="" id=d88552e1033> <b> <i>Inflammatory and autoimmune diseases.</i> </b> A large spectrum of diseases of the immune system involves an activation of JAKs through autocrine or paracrine cytokine loops<sup><a href="#ref-62">62</a></sup>. In inflammatory pathologies, such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease, and alopecia areata, the most important JAK to be targeted is JAK1<sup><a href="#ref-62">62</a></sup>. In autoimmune disease, JAK1 is also the main JAK to be targeted as both the IL-6 and the type 1 interferon (IFN) pathways are involved. Blocking JAK1/2 in graft-versus-host disease (GVHD) is useful as type II IFN and IL-6 are pathogenic<sup><a href="#ref-63">63</a></sup>. Lastly, JAK inhibition can be useful to curb oncogenic inflammatory responses in a wide range of solid tumors.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d88552e1058>JAK inhibitors</h2><p class="" id=d88552e1061>Several types of inhibitors exist according to their mechanism/region targeted in JAKs<sup><a href="#ref-64">64</a></sup>.</p><div class=section><a name=d88552e1068 class=n-a></a><h3 class=section-title>Type I inhibitors</h3><p class="" id=d88552e1073>Type I inhibitors target the ATP-binding site of the JAKs under the active conformation of the kinase domain (<a href="#f3">Figure 3B</a>)<sup><a href="#ref-64">64</a></sup>. All clinically tested inhibitors are type I. They differ in their specificity for each JAK. Many inhibitors target JAK2, JAK1, and eventually TYK2 (ruxolitinib, momelotinib, AZD1480, and baricitinib) or JAK3 and JAK1 (tofacitinib). Some are pan-JAK inhibitors (gandotinib, XL019, NVP-BSK805, peficitinib, and pyridone 6). Less frequently, they target only JAK2 (NS-018, pacritinib, CEP-33779, NVP-BVB808, TG101209, fedratinib, and AZD960), JAK1 (filgotinib and itacitinib), or JAK3 (decernotinib, janex1, and JAK3-IN-1). However, they also target other kinases, in particular FLT3 (pacritinib, NVP-BVB808, TG101209, and fedratinib), Src (NS018), or Aurora A (AZD1480) (<a href="#T1">Table 1</a> and <a href="#f3">Figure 3B</a>).</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. JAK inhibitors, their targets, and their applications to pathologies.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d88552e1100 class=n-a></a><thead><a name=d88552e1102 class=n-a></a><tr><a name=d88552e1104 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d88552e1106 class=n-a></a>Inhibitors</th><th align=left colspan=1 rowspan=1><a name=d88552e1109 class=n-a></a>Selectivity</th><th align=left colspan=1 rowspan=1><a name=d88552e1112 class=n-a></a>Off-<br class=br>target</th><th align=left colspan=1 rowspan=1><a name=d88552e1117 class=n-a></a>Diseases</th><th align=left colspan=1 rowspan=1><a name=d88552e1120 class=n-a></a>Clinical phases</th></tr></thead><tbody><a name=d88552e1125 class=n-a></a><tr><a name=d88552e1127 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1129 class=n-a></a> <b>Type I</b> </td><td colspan=1 rowspan=1><a name=d88552e1135 class=n-a></a></td><td colspan=1 rowspan=1><a name=d88552e1137 class=n-a></a></td><td colspan=1 rowspan=1><a name=d88552e1139 class=n-a></a></td><td colspan=1 rowspan=1><a name=d88552e1141 class=n-a></a></td></tr><tr><a name=d88552e1144 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1146 class=n-a></a>Ruxolitinib</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1149 class=n-a></a>JAK2&gt;JAK1&gt;JAK3</td><td colspan=1 rowspan=1><a name=d88552e1152 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1154 class=n-a></a>MF and hydroxyurea resistant or intolerant PV<br class=br><br class=br>Refractory leukemia (post-MPN leukemia)<br class=br><br class=br>Pancreatic cancers<br class=br><br class=br><br class=br><br class=br><br class=br>Corticosteroid refractory-GVHD<br class=br><br class=br>Psoriasis<br class=br><br class=br>Alopecia<br class=br><br class=br><br class=br>Vitiligo</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1180 class=n-a></a>FDA-approved<sup><a href="#ref-77">77</a>–<a href="#ref-79">79</a></sup><br class=br><br class=br><br class=br>Phase 2<sup><a href="#ref-80">80</a></sup><br class=br><br class=br><br class=br>Phase 2 in combination<br class=br>with capecitabine (after<br class=br>gemcitabine failure)<sup><a href="#ref-81">81</a></sup><br class=br><br class=br>In evaluation<sup><a href="#ref-82">82</a></sup><br class=br><br class=br>Phase 2<sup><a href="#ref-83">83</a></sup><br class=br><br class=br>Open-label clinical trial<sup><a href="#ref-84">84</a></sup><br class=br><br class=br><br class=br>Case report<sup><a href="#ref-85">85</a></sup></td></tr><tr><a name=d88552e1235 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1237 class=n-a></a>Momelotinib<br class=br>(CYT-387)</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1242 class=n-a></a>JAK2&gt;JAK1&gt;JAK3</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1245 class=n-a></a>ALK-2<br class=br>TBK1<br class=br>IKKε</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1252 class=n-a></a>PMF<br class=br>Post PV/ET MF<br class=br><br class=br><br class=br>PV/ET</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1261 class=n-a></a>Phase 3 - SIMPLIFY-1/2<br class=br>(Stopped)<sup><a href="#ref-86">86</a></sup><br class=br><br class=br>Phase 2 (terminated)<sup><a href="#ref-87">87</a></sup></td></tr><tr><a name=d88552e1276 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1278 class=n-a></a>AZD1480</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1281 class=n-a></a>JAK2&gt;JAK1</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1284 class=n-a></a>Aurora A<br class=br>FGFR1<br class=br>FLT4</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1291 class=n-a></a>PMF<br class=br>Post PV/ET MF<br class=br><br class=br>B-ALL<br class=br><br class=br><br class=br>Solid tumors</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1303 class=n-a></a>Phase 1<br class=br>(completed)<sup><a href="#ref-88">88</a></sup><br class=br><br class=br>In evaluation<br class=br>(preclinic)<sup><a href="#ref-89">89</a></sup><br class=br><br class=br>Phase 1<br class=br>(terminated)<sup><a href="#ref-90">90</a></sup></td></tr><tr><a name=d88552e1329 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1331 class=n-a></a>Baricitinib<br class=br>(INCB-028050)</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1336 class=n-a></a>JAK2&gt;JAK1</td><td colspan=1 rowspan=1><a name=d88552e1339 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1341 class=n-a></a>Rheumatoid arthritis<br class=br><br class=br><br class=br><br class=br>Psoriasis</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1349 class=n-a></a>Phase 3 (FDA approval in<br class=br>process, EMA-approved)<sup><a href="#ref-91">91</a></sup><br class=br><br class=br>Phase 2<sup><a href="#ref-92">92</a></sup></td></tr><tr><a name=d88552e1365 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1367 class=n-a></a>Tofacitinib</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1370 class=n-a></a>JAK1&gt;JAK3</td><td colspan=1 rowspan=1><a name=d88552e1373 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1375 class=n-a></a>Methothrexate-resistant rheumatoid arthritis<br class=br><br class=br>Crohn’s<br class=br><br class=br>Psoriasis<br class=br><br class=br>Alopecia areata<br class=br><br class=br>Dermatomyositis, vitiligo</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1391 class=n-a></a>FDA-approved<sup><a href="#ref-93">93</a></sup><br class=br><br class=br>Phase 2<sup><a href="#ref-94">94</a></sup><br class=br><br class=br>Phase 3<sup><a href="#ref-95">95</a></sup><br class=br><br class=br>Phase 2<sup><a href="#ref-96">96</a></sup><br class=br><br class=br>Case report<sup><a href="#ref-96">96</a></sup></td></tr><tr><a name=d88552e1423 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1425 class=n-a></a>Gandotinib<br class=br>(LY2784544)</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1430 class=n-a></a>Pan-JAK<br class=br>JAK2V617F&gt;JAK2 </td><td colspan=1 rowspan=1><a name=d88552e1435 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1437 class=n-a></a>JAK2V617F-positive MF, ET and PV patients</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1440 class=n-a></a>Phase 1<sup><a href="#ref-97">97</a></sup><br class=br>Phase 2 (in progress)</td></tr><tr><a name=d88552e1449 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1451 class=n-a></a>XL019</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1454 class=n-a></a>Pan-JAK</td><td colspan=1 rowspan=1><a name=d88552e1457 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1459 class=n-a></a>PV, MF</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1462 class=n-a></a>Phase 1<br class=br>(terminated)<sup><a href="#ref-98">98</a></sup></td></tr><tr><a name=d88552e1471 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1473 class=n-a></a>NVP-BSK805</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1476 class=n-a></a>JAK2</td><td colspan=1 rowspan=1><a name=d88552e1479 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1481 class=n-a></a>JAK2V617F</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1484 class=n-a></a>Cellular models<sup><a href="#ref-99">99</a></sup></td></tr><tr><a name=d88552e1491 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1493 class=n-a></a>NS-018</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1496 class=n-a></a>JAK2V617F&gt;JAK2</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1499 class=n-a></a>Src</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1502 class=n-a></a>PMF, post PV/ET MF patients<br class=br><br class=br>JAK2V617F selective</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1508 class=n-a></a>Phase 2<sup><a href="#ref-12">12</a></sup><br class=br><br class=br>In vitro<sup><a href="#ref-100">100</a></sup></td></tr><tr><a name=d88552e1521 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1523 class=n-a></a>Pacritinib<br class=br>(SB11518)</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1528 class=n-a></a>JAK2</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1531 class=n-a></a>FLT3</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1534 class=n-a></a>MF</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1537 class=n-a></a>Phase 3<br class=br>PERSIST-1<sup><a href="#ref-101">101</a></sup>,<br class=br>PERSIST-2<sup><a href="#ref-102">102</a></sup><br class=br>PAC203 study evaluating<br class=br>the effect of lower doses</td></tr><tr><a name=d88552e1557 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1559 class=n-a></a>CEP-33779</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1562 class=n-a></a>JAK2</td><td colspan=1 rowspan=1><a name=d88552e1565 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1567 class=n-a></a>Rheumatoid arthritis, colorectal cancer, lupus nephritis</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1570 class=n-a></a>Preclinical mouse models<sup><a href="#ref-103">103</a></sup></td></tr><tr><a name=d88552e1577 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1579 class=n-a></a>NVP-BVB808</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1582 class=n-a></a>JAK2</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1585 class=n-a></a>FLT3</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1588 class=n-a></a>MPN</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1591 class=n-a></a>Cell lines<sup><a href="#ref-104">104</a></sup></td></tr><tr><a name=d88552e1598 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1600 class=n-a></a>TG101209</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1603 class=n-a></a>JAK2</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1606 class=n-a></a>FLT3</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1609 class=n-a></a>MPN, systemic sclerosis</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1612 class=n-a></a>Cellular models<sup><a href="#ref-105">105</a></sup></td></tr><tr><a name=d88552e1619 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1621 class=n-a></a>Fedratinib<br class=br>(TG101348)</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1626 class=n-a></a>JAK2</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1629 class=n-a></a>FLT3<br class=br>BRD4</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1634 class=n-a></a>MF</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1637 class=n-a></a>Phase 3<br class=br>JAKARTA<sup><a href="#ref-106">106</a></sup> FDA removed<br class=br>the clinical hold in August<br class=br>2017</td></tr><tr><a name=d88552e1651 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1653 class=n-a></a>AZ960</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1656 class=n-a></a>JAK2</td><td colspan=1 rowspan=1><a name=d88552e1659 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1661 class=n-a></a>ATL, other leukemia</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1664 class=n-a></a>Cell lines</td></tr><tr><a name=d88552e1668 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1670 class=n-a></a>Filgotinib<br class=br>(GLPG0634)</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1675 class=n-a></a>JAK1&gt;JAK2</td><td colspan=1 rowspan=1><a name=d88552e1678 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1680 class=n-a></a>Rheumatoid arthritis<br class=br>Bowel and Crohn’s diseases<br class=br>Lupus and psoriasis</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1687 class=n-a></a>Phase 3<sup><a href="#ref-107">107</a></sup><br class=br>Phase 2<sup><a href="#ref-108">108</a></sup><br class=br>Phase 2<sup><a href="#ref-109">109</a></sup></td></tr><tr><a name=d88552e1705 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1707 class=n-a></a>Itacitinib<br class=br>(INCB-039110)</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1712 class=n-a></a>JAK1</td><td colspan=1 rowspan=1><a name=d88552e1715 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1717 class=n-a></a>MF<br class=br><br class=br><br class=br><br class=br>Psoriasis<br class=br><br class=br>Non-small cell lung cancer<br class=br><br class=br><br class=br><br class=br><br class=br><br class=br>GVHD<br class=br><br class=br><br class=br><br class=br><br class=br><br class=br><br class=br>B-cell lymphoma<br class=br><br class=br><br class=br><br class=br><br class=br><br class=br>BRAF-mutant melanoma and other solid tumors</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1752 class=n-a></a>Phase 2<br class=br>(alone or in combination with<br class=br>low-dose of ruxolitinib)<sup><a href="#ref-110">110</a></sup><br class=br>Phase 2<sup><a href="#ref-111">111</a></sup><br class=br><br class=br>Phase 2<br class=br>(combination with EGFR<br class=br>inhibitor, osimertinib)<br class=br>(in progress)<br class=br><br class=br>Phase 3<br class=br>(combination with corticosteroids)<br class=br>(in progress)<br class=br><br class=br>Phase 1/2<br class=br>(combination with BTK inhibitor, ibrutinib)<br class=br>(in progress)<br class=br><br class=br>Phase 1<br class=br>(in combination with MAPK inhibitors, dabrafenib or trametinib)<br class=br>(in progress)</td></tr><tr><a name=d88552e1801 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1803 class=n-a></a>INCB52793</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1806 class=n-a></a>JAK1</td><td colspan=1 rowspan=1><a name=d88552e1809 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1811 class=n-a></a>Advanced malignancies</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1814 class=n-a></a>Phase 1 (in progress)</td></tr><tr><a name=d88552e1818 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1820 class=n-a></a>PF-04965842</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1823 class=n-a></a>JAK1</td><td colspan=1 rowspan=1><a name=d88552e1826 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1828 class=n-a></a>Moderate to severe psoriasis</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1831 class=n-a></a>Phase 2<sup><a href="#ref-112">112</a></sup></td></tr><tr><a name=d88552e1838 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1840 class=n-a></a>Upadacitinib<br class=br>(ABT-494)</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1845 class=n-a></a>JAK1</td><td colspan=1 rowspan=1><a name=d88552e1848 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1850 class=n-a></a>Rheumatoid arthritis</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1853 class=n-a></a>Phase 2<sup><a href="#ref-113">113</a></sup><br class=br>Phase 3 (in progress)</td></tr><tr><a name=d88552e1862 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1864 class=n-a></a>Decernotinib<br class=br>(VX-509)</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1869 class=n-a></a>JAK3</td><td colspan=1 rowspan=1><a name=d88552e1872 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1874 class=n-a></a>Rheumatoid arthritis</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1877 class=n-a></a>Phase 2/3<sup><a href="#ref-114">114</a></sup></td></tr><tr><a name=d88552e1884 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1886 class=n-a></a>WHI-P131/<br class=br>JANEX-1</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1891 class=n-a></a>JAK3</td><td colspan=1 rowspan=1><a name=d88552e1894 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1896 class=n-a></a>GVHD</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1899 class=n-a></a>Preclinical mouse model<sup><a href="#ref-115">115</a></sup></td></tr><tr><a name=d88552e1907 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1909 class=n-a></a>JAK3-IN-1</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1912 class=n-a></a>JAK3</td><td colspan=1 rowspan=1><a name=d88552e1915 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1917 class=n-a></a>N/A</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1920 class=n-a></a>N/A</td></tr><tr><a name=d88552e1924 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1926 class=n-a></a>Peficitinib<br class=br>(ASP015K)</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1931 class=n-a></a>JAK3</td><td colspan=1 rowspan=1><a name=d88552e1934 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1936 class=n-a></a>Psoriasis<br class=br>Rheumatoid arthritis</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1941 class=n-a></a>Phase 2<sup><a href="#ref-116">116</a></sup><br class=br>Phase 2<sup><a href="#ref-117">117</a></sup></td></tr><tr><a name=d88552e1953 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1955 class=n-a></a> <b>Type II</b> </td><td colspan=1 rowspan=1><a name=d88552e1961 class=n-a></a></td><td colspan=1 rowspan=1><a name=d88552e1963 class=n-a></a></td><td colspan=1 rowspan=1><a name=d88552e1965 class=n-a></a></td><td colspan=1 rowspan=1><a name=d88552e1967 class=n-a></a></td></tr><tr><a name=d88552e1970 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1972 class=n-a></a>NVP-BBT594</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1975 class=n-a></a>JAK2</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1978 class=n-a></a>BCR-ABL KDR FLT3<br class=br>RET</td><td colspan=1 rowspan=1><a name=d88552e1983 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d88552e1985 class=n-a></a>Cellular models<sup><a href="#ref-14">14</a></sup></td></tr><tr><a name=d88552e1992 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e1994 class=n-a></a>NVP-CHZ868</td><td colspan=1 rowspan=1 valign=top><a name=d88552e1997 class=n-a></a>JAK2</td><td colspan=1 rowspan=1 valign=top><a name=d88552e2000 class=n-a></a>KIT,<br class=br>PDGFR<br class=br>VEGFR</td><td colspan=1 rowspan=1 valign=top><a name=d88552e2007 class=n-a></a>MPN<br class=br>B-ALL</td><td colspan=1 rowspan=1 valign=top><a name=d88552e2012 class=n-a></a>Preclinical mouse models<sup><a href="#ref-75">75</a></sup></td></tr><tr><a name=d88552e2019 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e2021 class=n-a></a> <b>Allosteric</b><br class=br><b>inhibitors</b> </td><td colspan=1 rowspan=1><a name=d88552e2030 class=n-a></a></td><td colspan=1 rowspan=1><a name=d88552e2032 class=n-a></a></td><td colspan=1 rowspan=1><a name=d88552e2034 class=n-a></a></td><td colspan=1 rowspan=1><a name=d88552e2036 class=n-a></a></td></tr><tr><a name=d88552e2040 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e2042 class=n-a></a>LS104</td><td colspan=1 rowspan=1 valign=top><a name=d88552e2045 class=n-a></a>JAK2</td><td colspan=1 rowspan=1 valign=top><a name=d88552e2048 class=n-a></a>BCR-<br class=br>ABL</td><td colspan=1 rowspan=1 valign=top><a name=d88552e2053 class=n-a></a>MPN</td><td colspan=1 rowspan=1 valign=top><a name=d88552e2056 class=n-a></a>JAK2V617F<br class=br>cell lines<sup><a href="#ref-118">118</a></sup></td></tr><tr><a name=d88552e2065 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d88552e2067 class=n-a></a>ON044580</td><td colspan=1 rowspan=1 valign=top><a name=d88552e2070 class=n-a></a>JAK2</td><td colspan=1 rowspan=1 valign=top><a name=d88552e2073 class=n-a></a>BCR-<br class=br>ABL</td><td colspan=1 rowspan=1 valign=top><a name=d88552e2078 class=n-a></a>MPN</td><td colspan=1 rowspan=1 valign=top><a name=d88552e2081 class=n-a></a>BCR-ABL<br class=br>cell lines<sup><a href="#ref-119">119</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d88552e2094 class=n-a></a><p id=d88552e2096> ATL, adult T-cell leukemia; B-ALL, B-cell acute lymphoblastic leukemia; BTK, Bruton’s tyrosine kinase; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; ET, essential thrombocythemia; FDA, US Food and Drug Administration; GVHD, graft-versus-host disease; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; MF, myelofibrosis; MPN, myeloproliferative neoplasm; N/A, not applicable; PMF, primary myelofibrosis; PV, polycythemia vera.</p></div></div></div><p class="" id=d88552e2102>The differences in specificities for JAK are the basis for the different trials: JAK2 specificity for MPNs and certain malignant disorders<sup><a href="#ref-65">65</a>,<a href="#ref-66">66</a></sup> and JAK1 and JAK3 for inflammation and auto-immune diseases<sup><a href="#ref-67">67</a></sup>. The clinical toxicity can be related to the precise JAK protein that is inhibited—hematological toxicity, eventually immune suppression for JAK2<sup><a href="#ref-66">66</a></sup>,—immune suppression and long-term effects on hematopoietic stem cells (HSCs) for JAK1 and JAK3<sup><a href="#ref-68">68</a></sup>. It can be also due to an off-target inhibition. It has been suggested that the gastrointestinal toxicity was related to FLT3 inhibition<sup><a href="#ref-69">69</a></sup> and the Wernicke encephalitis observed in rare patients treated with fedratinib to inhibition of thiamine uptake<sup><a href="#ref-70">70</a></sup>.</p><p class="" id=d88552e2133>Currently, only three JAK inhibitors are US Food and Drug Administration (FDA) or European Medicines Agency (EMA)-approved for treatment: ruxolitinib for the treatment of MF and hydroxyurea (HU)-resistant or -intolerant PVs<sup><a href="#ref-65">65</a></sup>, tofacitinib and Baricitinib for the treatment of methotrexate-resistant RA<sup><a href="#ref-71">71</a></sup>.</p><p class="" id=d88552e2145>The major limitation of type I inhibitors that bind to active state kinases is that while they block catalysis they allow increased phosphorylation of the activation loop on Y1007, which upon overexpression of JAK2 or other JAKs can create heteromeric JAK complexes that re-set signaling<sup><a href="#ref-72">72</a></sup>. This might explain why resistance to JAK2 inhibition is not related to mutations but to functional inhibition<sup><a href="#ref-73">73</a></sup>.</p></div><div class=section><a name=d88552e2157 class=n-a></a><h3 class=section-title>Type II inhibitors</h3><p class="" id=d88552e2162>The type II inhibitors bind to the ATP-binding pocket of kinase domains in inactive conformation, and the F of the DFG pocket is in an out conformation (<a href="#f3">Figure 3C</a>)<sup><a href="#ref-64">64</a>,<a href="#ref-74">74</a></sup>. Inhibition is more efficient and is not reversed by drug detachment<sup><a href="#ref-14">14</a></sup>. The best example is imatinib and the second generation of BCR-ABL inhibitors<sup><a href="#ref-74">74</a></sup>. Two type II JAK2 inhibitors (NVP-BBT594 and NVP-CHZ868) have been developed. NVP-CHZ868 has been used in preclinical models and was very effective<sup><a href="#ref-75">75</a>,<a href="#ref-76">76</a></sup>. Both inhibitors were not amenable for drug development. Owing to their powerful activity, the type II JAK2 inhibitors present the risk of inducing profound cytopenia, limiting its future use in PV or ET.</p></div><div class=section><a name=d88552e2191 class=n-a></a><h3 class=section-title>Allosteric inhibitors</h3><p class="" id=d88552e2196>Allosteric inhibitors are molecules that do not bind to the active kinase site but to another site<sup><a href="#ref-64">64</a></sup>. Theoretically, they would be more specific than an ATP-pocket inhibitor given the high homology of ATP-binding sites. Allosteric inhibition could be interesting to specifically target only the mutated JAKs (<i>JAK2</i>V617F: 60–70% of MPNs and JAK2 exon 12: 1%) as JAK2WT is indispensable for normal hematopoiesis. An efficient JAK2WT inhibition will always lead to a cytopenia.</p><p class="" id=d88552e2206>Within allosteric inhibitors, type III bind to a site close to the ATP-binding site while type IV bind to an allosteric site distant from the ATP-binding site. This means that in the case of <i>JAK2</i>V617F it might be important to target the pseudokinase domain (type IV inhibitors, see last section). To our knowledge, there is currently no allosteric inhibitor of <i>JAK2</i>V617F in development.</p></div><div class=section><a name=d88552e2217 class=n-a></a><h3 class=section-title>Other types of inhibitors</h3><p class="" id=d88552e2222>For kinases other than JAKs, additional types of inhibitors have been developed<sup><a href="#ref-64">64</a></sup>:</p><p class="" id=d88552e2229>Type V. Such inhibitors reversibly bind to two sites of the kinase domain.</p><p class="" id=d88552e2232>Covalent. They irreversibly bind on a nucleophilic residue (usually a cysteine) located in the ATP-binding site.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d88552e2239>JAK inhibitor therapies</h2><div class=section><a name=d88552e2242 class=n-a></a><h3 class=section-title> <i>BCR-ABL</i> –negative MPNs</h3><p class="" id=d88552e2250>Triggered by the discovery of <i>JAK2</i>V617F, JAK2 inhibitors have been developed, but none of them is specific to the mutant protein and most of them also target other kinases such as JAK1 and FLT3. One advantage is that their use can be extended to the <i>JAK2</i>V617F-negative MPNs or other pathologies associated with JAK2 activation that include inflammatory diseases and certain other cancers. Theoretically, it is not conceivable to completely inhibit JAK2 in the long term, because this will lead to a profound cytopenia and eventually aplastic anemia. Thus, these inhibitors can be used because they only partially inhibit JAK2 <i>in vivo</i> for different reasons (pharmacokinetics and resistance). This explains why such inhibitors give similar clinical results in MF’s improving quality of life, decreasing the splenomegaly, and improving survival. The evolution of the disease is not changed, nor apparently is the rate of MPN transformation. The differences between inhibitors concern the side effects that may essentially be related to distinct off-targets (<a href="#T1">Table 1</a>).</p><p class="" id=d88552e2265> <b> <i>Ruxolitinib.</i> </b> Ruxolitinib (<a href="#f3">Figure 3B</a> and D) was the first JAK2 inhibitor approved for therapy of MF (high and intermediate risks). It is now the only JAK inhibitor for which a long-term follow-up has been reached. In intermediate-2 and high-risk MF, a very significant effect is found in more than 50% of the patients with a reduced spleen size (clinical trials COMFORT-1 and COMFORT-2) at any point in the trial and even a more marked effect on the general symptoms, in particular the pruritus<sup><a href="#ref-77">77</a>–<a href="#ref-79">79</a></sup>. These results have been extended to low- and intermediate-1 risk MF<sup><a href="#ref-120">120</a></sup>. In HU-refractory PVs, ruxolitinib allows the control of hematocrit in more than 60% of patients and induces a spleen volume reduction in 38% of cases at 32 weeks. In addition, a molecular decrease of <i>JAK2</i>V617F allele burden reaching a mean of 40% at 208 weeks was observed<sup><a href="#ref-78">78</a>,<a href="#ref-121">121</a></sup>. In HU-resistant or -intolerant ET, there are divergent results. In one study, ruxolitinib offered no advantage compared with other therapies in the control of the thrombocytosis and disease complications but did alleviate general symptoms and pruritus<sup><a href="#ref-122">122</a></sup>. In the other<sup><a href="#ref-123">123</a></sup>, which was an open-label phase 2 trial, ruxolitinib induced a meaningful reduction in platelet levels and attenuated ET-related symptoms. These preliminary results seemed superior to historically observed results, but this study was done in the absence of a comparison with another treatment.</p><p class="" id=d88552e2307>Overall, ruxolitinib is a well-tolerated oral treatment with approximately 25–33% of adverse effects. The main toxicities are hematological, moderate anemia that may correct with time, and thrombocytopenia, which can be very severe in high-risk MF. Weight gain is also observed with possible abnormalities in lipid metabolism. Middle-term toxicity is an immune suppression that may be responsible for reactivation of viral infections, particularly herpes zoster and HIV1 and bacterial infections such as pneumonia, tuberculosis reactivation and urinary tract infections<sup><a href="#ref-124">124</a>,<a href="#ref-125">125</a></sup>. Long-term monitoring will be important because ruxolitinib decreases natural killer cell functions with a potential risk of solid tumor and lymphoma development<sup><a href="#ref-126">126</a>,<a href="#ref-127">127</a></sup>. This is particularly important if indications are extended to low-risk MF, PV, and ET. Analysis of patients treated for several years with ruxolitinb indicates an increase in survival in MF, but progression to leukemia is not significantly different<sup><a href="#ref-128">128</a></sup>. It is possible that most pro-survival effects derive from its palliative anti-inflammatory effects<sup><a href="#ref-65">65</a></sup>.</p><p class="" id=d88552e2332> <b> <i>Other JAK2 inhibitors.</i> </b> Momelotinib (CYT38) (<a href="#f3">Figure 3D</a>) is a JAK1/JAK2 inhibitor that has shown activity resembling ruxolitinib with respect to spleen size reduction and constitutional symptom alleviation<sup><a href="#ref-129">129</a>–<a href="#ref-131">131</a></sup>. Importantly, momelotinib was shown to ameliorate anemia, which is a major concern in MF. The mechanism appears to be the reduction of hepcidin production through a direct inhibition of the activin receptor-like kinase-2 (ALK-2)<sup><a href="#ref-132">132</a></sup>. Thus, momelotinib was thought to be an alternative to ruxolitinib for patients with anemia. These promising results led to the opening of a phase III trial for the SIMPLIFY-1 and -2 studies in MF. However, the results of the two clinical trials did not show a major advantage of momelotinib on ruxolitinib, although momelotinib was associated with a decrease in transfusion requirement<sup><a href="#ref-86">86</a></sup>. Momelotinib development has been stopped.</p><p class="" id=d88552e2360>NS-018 (<a href="#f3">Figure 3D</a>) is a JAK2/Src inhibitor that has been assessed in patients with <i>JAK2</i>V617F-positive MF, ET, and PV. NS-018 shows an apparent increased potency for the JAK2V617F mutant in mouse models, possibly leading to less immunosuppressive effects<sup><a href="#ref-100">100</a></sup>. It was tested in MF with symptom improvement but minor impact on the numbers of <i>JAK2</i>V617F cells<sup><a href="#ref-133">133</a></sup>. Gandotinib (LY2784544) (<a href="#f3">Figure 3D</a>) is a potent JAK2 inhibitor, which also exhibits a certain selectivity toward JAK2V617F. It was evaluated for safety and tolerability in ET, PV, and MF<sup><a href="#ref-97">97</a></sup>.</p><p class="" id=d88552e2388>Pacritinib (SB1518) (<a href="#f3">Figure 3D</a>) is a JAK2/FLT3 inhibitor. Promising results were obtained in phase 1–2 clinical trials. It showed good activity in patients with less immunosuppressive effects<sup><a href="#ref-134">134</a></sup>. Pacritinib could be administered to patients with low platelet levels, as it does not induce thrombocytopenia. The reasons behind this feature are unclear; they could be linked to reduced specificity for MPL/JAK2 complexes. Subsequently, two phase 3 clinical trials (PERSIST 1 and 2) were started with different doses of pacritinib. In 2016, the FDA put a complete clinical hold on the trials because of an excess of intracranial hemorrhage and cardiac failure in treated patients<sup><a href="#ref-135">135</a></sup>. This hold was lifted in 2017<sup><a href="#ref-136">136</a></sup>. As a consequence, CTI BioPharma has just launched the PAC203 study evaluating the effect of pacritinib at different doses.</p><p class="" id=d88552e2406>Fedratinib (TG101348) (<a href="#f3">Figure 3D</a>) was assessed during the JAKARTA trials with interesting clinical results, including fibrosis reduction<sup><a href="#ref-137">137</a>–<a href="#ref-139">139</a></sup>, but rare patients developed Wernicke encephalopathy, which led to its stop<sup><a href="#ref-139">139</a></sup>. It was assumed that it was related to an inhibition of thiamine uptake, although fedratinib does not lead to inhibition of thiamine uptake in rats<sup><a href="#ref-70">70</a>,<a href="#ref-140">140</a></sup>. FDA removed the clinical hold in august 2017 and clinical trials are being planned in 2018.</p><p class="" id=d88552e2430>JAK1 inhibition has also been proposed in MPNs, as an anti-inflammatory strategy, and an alternative to JAK2 inhibitors to avoid anemia and thrombocytopenia<sup><a href="#ref-65">65</a>,<a href="#ref-66">66</a></sup>. A preliminary study has produced mixed results with a modest reduction in spleen size<sup><a href="#ref-110">110</a></sup>. Recently, it has been demonstrated that JAK1 plays essential and non-redundant roles at the level of HSC and therefore long-term JAK1 inhibition might have negative effects on HSCs<sup><a href="#ref-68">68</a></sup>.</p></div><div class=section><a name=d88552e2449 class=n-a></a><h3 class=section-title>Other malignant disorders</h3><p class="" id=d88552e2454>Ruxolitinib was also used in refractory leukemia, including post-MPN leukemia, and 3 out of 18 patients achieved complete remission<sup><a href="#ref-80">80</a></sup>. Ruxolitinib was unexpectedly used in combination with chemotherapeutic agents in solid cancers (pancreatic and lung cancer) and there was some benefit<sup><a href="#ref-141">141</a></sup>. This was based on JAK1 involvement in the signaling of several cytokine receptors, inflammation, and possibly progression of the malignant clone<sup><a href="#ref-81">81</a>,<a href="#ref-142">142</a></sup>.</p><p class="" id=d88552e2472>Ruxolitinib has been used both in myeloid malignancies with JAK2 fusion proteins and in CNL with a very good initial response but was inefficient to cure the diseases<sup><a href="#ref-143">143</a>–<a href="#ref-146">146</a></sup>.</p><p class="" id=d88552e2482>Itacitinib (INCB39110), which is also a selective JAK1 inhibitor, is being tested in non-small cell lung cancer in combination with an epidermal growth factor receptor inhibitor. Another JAK1 inhibitor, INCB52793, is also in development in advanced malignancies.</p></div><div class=section><a name=d88552e2486 class=n-a></a><h3 class=section-title>Inflammatory and autoimmune diseases</h3><p class="" id=d88552e2491>JAK1 inhibitors have been used in inflammatory/immune diseases<sup><a href="#ref-67">67</a>,<a href="#ref-147">147</a></sup>. Tofacitinib was authorized by the FDA in RA<sup><a href="#ref-148">148</a></sup> but is currently being tested in Crohn’s disease, psoriasis, and other diseases<sup><a href="#ref-149">149</a>,<a href="#ref-150">150</a></sup>. It decreases inflammation particularly by lowering T-cell and macrophage infiltrates. Filgotinib is currently in phase 3 clinical trials in RA and Crohn’s disease and in phase 2 clinical trials in lupus and psoriasis. Itacitinib (INCB39110) is being tested in phase 2 trials in psoriasis and in MF with meaningful improvements.</p><p class="" id=d88552e2512>Ruxolitinib, also a good inhibitor of JAK1, was shown to reduce GVHD in mice and in patients with corticosteroid-refractory GVHD<sup><a href="#ref-82">82</a>,<a href="#ref-151">151</a></sup>. Indeed, in GVHD, severe complications are due to high levels of proinflammatory cytokines that are inhibited by ruxolitinib. Itacitinib will be assessed as monotherapy in GVHD.</p><p class="" id=d88552e2522>A JAK1 inhibitor, PF-04965842, is also in clinical trials in atopic dermatis and severe psoriasis<sup><a href="#ref-112">112</a></sup>. Both topical tofacitinib and ruxolitinib are tested for alopecia and vitiligo.</p><p class="" id=d88552e2529>Baricitinib (Olumiant), a JAK1/2 inhibitor (half maximal inhibitory concentration [IC<sub>50</sub>] values of 5.9 and 5.7 nM, respectively), has been initially identified by Incyte and subsequently developed by Eli Lilly and Company for RA. It also inhibits TYK2 (IC<sub>50</sub> of around 53 nM). A phase 3 clinical trial was conducted, and the molecule was approved by the EMA but not yet by the FDA<sup><a href="#ref-148">148</a>,<a href="#ref-152">152</a></sup>. It may be of interest in MPN treatment given its similarities with ruxolitinib but with a longer half-life (12.5 hours). Upadacitinib (ABT-494, AbbVie) is a highly selective JAK1 inhibitor that will enter phase 3 trials for RA, psoriasis, and ulcerative colitis.</p><p class="" id=d88552e2546>Two JAK3 inhibitors were evaluated. ASP015K, also designated JNJ-54781532, displays a moderate selectivity on JAK3 over JAK1 and JAK2. It was shown to induce efficacy and safety in psoriasis<sup><a href="#ref-116">116</a></sup>. It has demonstrated efficacy in preclinical models of RA and dermatitis. Decernolitinib is also a potent and selective inhibitor of JAK3 developed as a second-generation inhibitor in autoimmune diseases, particularly in RA. However, at high doses, it leads to anemia, indicating that its selectivity <i>in vivo</i> could be different<sup><a href="#ref-153">153</a></sup>.<i></i> In MPNs, these types of inhibitors could also be useful to decrease inflammation, especially in MF.</p><p class="" id=d88552e2562>The major drawback of these JAK1 and JAK3 inhibitors affecting the inflammatory response is that they can induce autoimmune diseases (thyroiditis or myocarditis) or can prime the development of many infections in patients with MPN. Furthermore, it appears that for the IL-2/IL-4/IL-7/IL-9/IL-15/IL-21 complexes, JAK1 is the initiating kinase for signaling, and a JAK3 that is inhibited can still fulfill its scaffolding role in the complex, its inhibition not giving results comparable to the absence of JAK3 by autosomal mutation<sup><a href="#ref-154">154</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d88552e2574>Perspectives in JAK inhibition</h2><p class="" id=d88552e2577>The goal of JAK2 inhibition in MPNs has switched from a curative therapy to a symptomatic and anti-inflammatory therapy with certain clinical benefits<sup><a href="#ref-65">65</a></sup>. However, this aim is far from what is expected for a targeted therapy<sup><a href="#ref-69">69</a></sup>. Although several <i>in vitro</i> studies identified potential kinase domain mutations that would give resistance to JAK2 inhibitors<sup><a href="#ref-155">155</a>,<a href="#ref-156">156</a></sup>, no such mutations were identified in patients<sup><a href="#ref-72">72</a></sup>, further arguing that the current inhibitors are weak. Thus, there is a need for new inhibitors or combination of therapies.</p><div class=section><a name=d88552e2602 class=n-a></a><h3 class=section-title>New inhibitors</h3><p class="" id=d88552e2607>First, a new generation of JAK2-specific compounds, including allosteric inhibitors targeting unique sequences in JAK2, should come to light. Such inhibitors would provide more specificity toward JAK2 or JAK2V617F, thereby ameliorating normal JAK2 inhibition-based immune suppression. Two inhibitors have been developed (LS104 and ON044580) that inhibit kinase activities in a non-ATP-competitive manner<sup><a href="#ref-118">118</a>,<a href="#ref-119">119</a></sup>. LS104 preferentially inhibits JAK2V617F kinase and can synergize with ATP-competitive inhibitors<sup><a href="#ref-118">118</a></sup>, whereas ON044580 inhibits BCR-ABL and its T315I mutant<sup><a href="#ref-119">119</a></sup>. The precise targeted residues remain unknown.</p><p class="" id=d88552e2625>Identification of allosteric sites in enzymes has been accomplished for several years and is the basis for the development of a new class of pharmaceuticals. One example is the development of the BCR-ABL allosteric inhibitor GNF-2 that can overcome the effect of resistant mutations and also exhibits an increased potency when used in combination with classic ATP-competitive inhibitors<sup><a href="#ref-157">157</a></sup>. Another example is the development of MEK allosteric inhibitors. It was shown that analogues of PD184352 could specifically bind to a unique region adjacent to the ATP pocket created by the displacement of the helix αC of the kinase in the active conformation<sup><a href="#ref-158">158</a></sup>.</p><p class="" id=d88552e2636>As the main conformational difference between JAK2V617F and JAK2WT is around the helix αC of the pseudokinase JH2 domain<sup><a href="#ref-159">159</a></sup>, a rational design of similar molecules targeting this region could be efficient (<a href="#f4">Figure 4</a>). Recent structural and mechanistic data on JH2 V617F might help in designing such small molecules. Moreover, targeting JH2 might become feasible as shown by the recent publication of co-crystals of JH2 with several compounds. Future therapeutics should target small conformational changes that are specific for a particular mutant protein or its constitutive activity.</p><div class="fig panel clearfix"><a name=f4 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/14282/a6b7053e-1d6f-49e9-8144-1be91b87572d_figure4.gif"><img alt="a6b7053e-1d6f-49e9-8144-1be91b87572d_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/14282/a6b7053e-1d6f-49e9-8144-1be91b87572d_figure4.gif"></a><div class=caption><h3>Figure 4. Graphic representation of the V617F-activation mechanism in Janus kinase2 (JAK2).</h3><p id=d88552e2656>The V617F activation has been suggested to derive from a combination of several molecular events triggered from a region surrounding the JH2 αC but also involving the SH2-JH2 linker. Phenylalanine 617 interacts with F594 and F595 from the JH2 αC and F537 from the SH2-JH2 linker, as supported by structural data<sup><a href="#ref-9">9</a>,<a href="#ref-159">159</a></sup>, then induces putative conformational changes that are transmitted to the adjacent catalytic kinase domain where activation is initiated. Targeting the ATP-binding pocket of JH2 that is spatially close the αC represents an appealing approach for specific targeting of the mutant JAK2V617F. Small molecules, such as BI-D1870 (as represented here<sup><a href="#ref-160">160</a></sup>), have been co-crystallized as bound to the JH2 ATP-binding site. The use of amendable compounds targeting the JH2 pocket has recently become a tantalizing concept and will represent the future challenge for drug design.</p></div></div><p class="" id=d88552e2675>The activating mutation, <i>JAK2</i>V617F, is located in the pseudokinase domain of JAK2 and allosterically regulates the activity of JAK2 kinase domain. Another strategy would be to interrupt these specific intramolecular changes induced by V617F on the kinase domain of JAK2. The aromatic phenylalanine at position 617 interacts with the αC helix phenylalanines 594 and 595<sup><a href="#ref-161">161</a></sup> and with phenylalanine 537 from the SH2-JH2 linker<sup><a href="#ref-9">9</a></sup> to produce an autonomous activation to the adjacent catalytically active domain, JH1 (<a href="#f4">Figure 4</a>). Both of these aberrant hydrophobic contacts induce critical conformational changes that can be visualized on the JH2 V617F crystal structures<sup><a href="#ref-9">9</a>,<a href="#ref-159">159</a></sup>. Any small molecules that would interfere with these specific atomic configurations exclusively present in the conformation of JAK2V617F would most likely generate mutant-specific inhibitors. Evidence was provided that V617F activates JAK2 through a community of residues across JAK2 (from JH2 to JH1 through the SH2-JH2 linker) and that reversing the charge of the negative residue, E596, located on the solvent-exposed face of the JH2 αC helix, can efficiently uncouple JAK2V617F activation from cytokine-induced activation, thereby restoring auto-inhibition of JAK2.</p><p class="" id=d88552e2699>Finally, methotrexate, a well-known drug used in autoimmune disease was shown to also inhibit the JAK/STAT pathway and in theory could be tested for selective effects on the MPN clones<sup><a href="#ref-162">162</a></sup>. An advantage of this treatment is its low cost, while its side effects are well known.</p></div><div class=section><a name=d88552e2707 class=n-a></a><h3 class=section-title>Combination of therapies</h3><p class="" id=d88552e2712>The goal of certain combinations is to improve the anemia of MF, which can be worsened by ruxolitinib<sup><a href="#ref-65">65</a></sup>. Trials have been performed in combination with androgen without benefit. Trials are ongoing with pomalidomide or thalidomide and also with sotartercept, an activin receptor IIa ligand trap<sup><a href="#ref-163">163</a></sup>. Treatment with erythropoiesis-stimulating agents is also conceivable, although they are theoretically antagonistic with JAK2 inhibitors<sup><a href="#ref-164">164</a></sup>.</p><p class="" id=d88552e2727>Downstream JAK2 are activations of STATs, PI3K-AKT/mTOR, and RAS-MAPK ERK1/2 (<a href="#f2">Figure 2</a>)<sup><a href="#ref-165">165</a></sup>. Specific inhibitors of STAT5 and STAT3 are now being tested in preclinical studies<sup><a href="#ref-166">166</a></sup>. A combination of JAK2 and STAT5 inhibitors might be effective in MPNs. In preclinical models, JAK2 and pan type I PI3K and mTOR inhibitors synergize to block JAK2V617F-induced proliferation<sup><a href="#ref-167">167</a>,<a href="#ref-168">168</a></sup> but less on mutant CALR-induced proliferation<sup><a href="#ref-18">18</a></sup>. Other molecules involved in the inhibition of the PI3K, AKT, or mTOR pathway were tested in preclinical models or clinical trials.</p><p class="" id=d88552e2752>The HSP90 chaperone is involved in JAK2 stability and is controlled via its acetylation status<sup><a href="#ref-169">169</a></sup>. HSP90 inhibitors or histone deacetylase inhibitors were tested<sup><a href="#ref-169">169</a></sup>. Notably, panobinostat and pracinostat were studied in combination with ruxolitinib in a phase 2 trial with a better spleen response in MF<sup><a href="#ref-170">170</a></sup>. Furthermore, a preliminary trial using an HSP90 inhibitor showed some clinical benefit<sup><a href="#ref-171">171</a></sup>. Combinations of ruxolitinib with CDK4/6 inhibitors, PIM1 kinase inhibitors, BH3 mimetics, or MDM2 inhibitors appear logical because they target molecules, which are downstream of JAK2 signaling, thus curbing any residual activation due to incomplete JAK2 inhibition due to short half-life of inhibitor and type I inhibition mechanism that allows rapid reactivation. Intriguingly, it has been reported that an association of ruxolitinib with pegylated interferon alpha was synergistic in a preliminary clinical trial, and a new larger clinical trial is ongoing<sup><a href="#ref-172">172</a></sup>. Normally, a JAK1 inhibitor should decrease interferon alpha signaling and should limit the effects of pegylated interferon; thus, the synergy might reflect how inefficiently ruxolitinib can actually inhibit JAKs <i>in vivo</i>. The main risk of all these different associations is to induce important cytopenia.</p><p class="" id=d88552e2779>In MF, it has also been suggested to combine ruxolitinib with MEK inhibitors and PRM-151, a molecule that inhibits differentiation of fibrocytes<sup><a href="#ref-173">173</a></sup>, which are implicated in fibrosis development<sup><a href="#ref-174">174</a></sup>. Both drugs exhibit an effect on bone marrow fibrosis in preclinical studies or in clinical trials<sup><a href="#ref-175">175</a></sup>. An inhibitor of hedgehog signaling pathway (LDE225) was also tested in phase I in ET/PV and MF with disappointing results<sup><a href="#ref-176">176</a></sup>. However, recent evidence points to targeting Gli1 in association with ruxolitinib because Gli1<sup>+</sup> mesenchymal cells may play a central role in fibrosis development<sup><a href="#ref-177">177</a></sup>.</p><p class="" id=d88552e2807>JAK2V617F can increase the protein methylation demonstrated by activation of PRMT5 arginine methyltransferase<sup><a href="#ref-178">178</a></sup>. It also prevents the binding of heterochromatin factor HP1 to chromatin<sup><a href="#ref-179">179</a></sup>. It is possible that some key genes could be hypermethylated as in many cancers. Therefore, it was postulated that demethylating agents such azacytidine and decitabine may have some impact. However, administered alone, they showed minor responses in two clinical trials<sup><a href="#ref-180">180</a>,<a href="#ref-181">181</a></sup>. They were thus combined with ruxolitinib in a few patients with MF and the clinical response was good.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d88552e2829>Conclusions</h2><p class="" id=d88552e2832>After the discovery of <i>JAK2</i>V617F and the demonstration that <i>BCR-ABL</i>–negative MPNs are driven by abnormal JAK2 activation, there were curative expectations for JAK inhibitors. Despite nearly 10 years of development in MPNs, only one JAK2 inhibitor (ruxolitinib) has been clinically approved. Most other inhibitors had their development stopped because of neurotoxicity or the absence of superiority compared with ruxolitinib. Only pacritinib (<a href="#f3">Figure 3B</a>) is still in phase 3 clinical testing and fedratinib is being reevaluated. Although ruxolitinib offers clear benefits for patients, its effects are quite limited on the disease itself in MF. On one hand, this may be explained by the additional mutations detected by MF clones, which act independently from JAK2 and which place MF at the boundary between MPN and MDS. On the other hand, ruxolitinib has a short half-life and acts as a type I inhibitor, which means that each time inhibitor is consumed, re-activation of JAK2 will occur.</p><p class="" id=d88552e2844>Thus, it seems important in PV and ET, which are JAK2-dependent MPNs, to obtain specific inhibitors of JAK2V617F or even to preferentially target the constitutive active JAK2 over cytokine-activated JAK2 in the cases of mutated <i>MPL</i> and <i>CALR</i> ET and MF. It is expected that such inhibitors will be less toxic and will really target the clonal disease. In MF, the low-hanging fruit of combination therapies could be a valuable approach that holds a risk for significant toxicities.</p><p class="" id=d88552e2853>An important finding of the clinical trials in MPNs was the discovery that JAK inhibition is a valuable approach for treatment of inflammatory diseases. Thus, it can be expected that one of the main applications of JAK inhibitors will be for inflammatory diseases, autoimmune diseases, and possibly other diseases, which may include an inflammatory response, including neurodegenerative disorders or cancers where inflammation contributes to oncogenesis.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d88552e1 class=n-a></a><h2 class=main-title id=d89133>Competing interests</h2><p class=metadata-entry><a name=d88552e206 class=n-a></a><p id=d88552e207> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d88552e1 class=n-a></a><h2 class=main-title id=d89135>Grant information</h2><p>This work was supported by grants from Ligue Nationale Contre le Cancer (‘Equipe labellisée 2016’ to WV and IP), Institut National du Cancer (PLBIO2015 to IP), MPN Research Foundation (IP), and Institut National de la Santé et de la Recherche Médicale (Inserm). The Laboratory of Excellence Globule Rouge-Excellence (IP and WV) is funded by the program ‘Investissements d’avenir’. SNC has received funding from the Ludwig Institute for Cancer Research, FRS-FNRS, Salus Sanguinis, Fondation contre le cancer, Project Action de Recherche Concerte of the Université Catholique de Louvain ARC10/15-027, the PAI (Interuniversity Support Program) Belgian Medical Genetics Initiative, and the Foundation ‘Les avions de Sébastien’ (Belgium). <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d88552e2860 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d89756>References</h2><div class="section ref-list"><a name=d88552e2860 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d88552e2867 class=n-a></a>Ihle JN: The <i>Janus</i> protein tyrosine kinases in hematopoietic cytokine signaling. <i>Semin Immunol.</i> 1995; <b>7</b>(4): 247–54. <a target=xrefwindow id=d88552e2878 href="http://www.ncbi.nlm.nih.gov/pubmed/8520029">PubMed Abstract </a> | <a target=xrefwindow id=d88552e2881 href="http://dx.doi.org/10.1006/smim.1995.0029">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d88552e2890 class=n-a></a>Constantinescu SN, Ghaffari S, Lodish HF: The Erythropoietin Receptor: Structure, Activation and Intracellular Signal Transduction. <i>Trends Endocrinol Metab.</i> 1999; <b>10</b>(1): 18–23. <a target=xrefwindow id=d88552e2898 href="http://www.ncbi.nlm.nih.gov/pubmed/10322390">PubMed Abstract </a> | <a target=xrefwindow id=d88552e2901 href="http://dx.doi.org/10.1016/S1043-2760(98)00101-5">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d88552e2910 class=n-a></a>Vainchenker W, Constantinescu SN: JAK/STAT signaling in hematological malignancies. <i>Oncogene.</i> 2013; <b>32</b>(21): 2601–13. <a target=xrefwindow id=d88552e2918 href="http://www.ncbi.nlm.nih.gov/pubmed/22869151">PubMed Abstract </a> | <a target=xrefwindow id=d88552e2921 href="http://dx.doi.org/10.1038/onc.2012.347">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d88552e2930 class=n-a></a>Rampal R, Al-Shahrour F, Abdel-Wahab O, <i> et al.</i>: Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. <i>Blood.</i> 2014; <b>123</b>(22): e123–33. <a target=xrefwindow id=d88552e2941 href="http://www.ncbi.nlm.nih.gov/pubmed/24740812">PubMed Abstract </a> | <a target=xrefwindow id=d88552e2944 href="http://dx.doi.org/10.1182/blood-2014-02-554634">Publisher Full Text </a> | <a target=xrefwindow id=d88552e2948 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4041169">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d88552e2957 class=n-a></a>Vainchenker W, Constantinescu SN, Plo I: Recent advances in understanding myelofibrosis and essential thrombocythemia [version 1; referees: 2 approved]. <i>F1000Res.</i> 2016; <b>5</b>: pii: F1000 Faculty Rev-700. <a target=xrefwindow id=d88552e2965 href="http://www.ncbi.nlm.nih.gov/pubmed/27134742">PubMed Abstract </a> | <a target=xrefwindow id=d88552e2968 href="http://dx.doi.org/10.12688/f1000research.8081.1">Publisher Full Text </a> | <a target=xrefwindow id=d88552e2971 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4841197">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d88552e2981 class=n-a></a>Huang LJ, Constantinescu SN, Lodish HF: The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. <i>Mol Cell.</i> 2001; <b>8</b>(6): 1327–38. <a target=xrefwindow id=d88552e2989 href="http://www.ncbi.nlm.nih.gov/pubmed/11779507">PubMed Abstract </a> | <a target=xrefwindow id=d88552e2992 href="http://dx.doi.org/10.1016/S1097-2765(01)00401-4">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d88552e3001 class=n-a></a>Ferrao R, Lupardus PJ: The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK-Receptor Interactions. <i>Front Endocrinol (Lausanne).</i> 2017; <b>8</b>: 71. <a target=xrefwindow id=d88552e3009 href="http://www.ncbi.nlm.nih.gov/pubmed/28458652">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3012 href="http://dx.doi.org/10.3389/fendo.2017.00071">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3015 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5394478">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d88552e3024 class=n-a></a>Leroy E, Dusa A, Colau D, <i> et al.</i>: Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix. <i>Biochem J.</i> 2016; <b>473</b>(11): 1579–91. <a target=xrefwindow id=d88552e3035 href="http://www.ncbi.nlm.nih.gov/pubmed/27029346">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3038 href="http://dx.doi.org/10.1042/BCJ20160085">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3042 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4888464">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d88552e3051 class=n-a></a>Toms AV, Deshpande A, McNally R, <i> et al.</i>: Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. <i>Nat Struct Mol Biol.</i> 2013; <b>20</b>(10): 1221–3. <a target=xrefwindow id=d88552e3062 href="http://www.ncbi.nlm.nih.gov/pubmed/24013208">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3065 href="http://dx.doi.org/10.1038/nsmb.2673">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3069 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3863620">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d88552e3078 class=n-a></a>Silvennoinen O, Ungureanu D, Niranjan Y, <i> et al.</i>: New insights into the structure and function of the pseudokinase domain in JAK2. <i>Biochem Soc Trans.</i> 2013; <b>41</b>(4): 1002–7. <a target=xrefwindow id=d88552e3089 href="http://www.ncbi.nlm.nih.gov/pubmed/23863170">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3092 href="http://dx.doi.org/10.1042/BST20130005">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d88552e3101 class=n-a></a>Royer Y, Staerk J, Costuleanu M, <i> et al.</i>: Janus kinases affect thrombopoietin receptor cell surface localization and stability. <i>J Biol Chem.</i> 2005; <b>280</b>(29): 27251–61. <a target=xrefwindow id=d88552e3112 href="http://www.ncbi.nlm.nih.gov/pubmed/15899890">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3115 href="http://dx.doi.org/10.1074/jbc.M501376200">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d88552e3125 class=n-a></a>Verstovsek S, Talpaz M, Ritchie EK, <i> et al.</i>: Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF). <i>Blood, 58th Annual Meeting and Exposition of the American-Society-of-Hematology</i>, San Diego, CA. 2016; <b>128</b>(22): 1936. <a target=xrefwindow id=d88552e3136 href="http://www.bloodjournal.org/content/128/22/1936?sso-checked=true">Reference Source</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d88552e3145 class=n-a></a>Duan Y, Chen L, Chen Y, <i> et al.</i>: c-Src binds to the cancer drug Ruxolitinib with an active conformation. <i>PLoS One.</i> 2014; <b>9</b>(9): e106225. <a target=xrefwindow id=d88552e3156 href="http://www.ncbi.nlm.nih.gov/pubmed/25197973">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3159 href="http://dx.doi.org/10.1371/journal.pone.0106225">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3163 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4157781">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d88552e3172 class=n-a></a>Andraos R, Qian Z, Bonenfant D, <i> et al.</i>: Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. <i>Cancer Discov.</i> 2012; <b>2</b>(6): 512–23. <a target=xrefwindow id=d88552e3183 href="http://www.ncbi.nlm.nih.gov/pubmed/22684457">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3186 href="http://dx.doi.org/10.1158/2159-8290.CD-11-0324">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3190 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5022112">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d88552e3199 class=n-a></a>Vainchenker W, Kralovics R: Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. <i>Blood.</i> 2017; <b>129</b>(6): 667–79. <a target=xrefwindow id=d88552e3207 href="http://www.ncbi.nlm.nih.gov/pubmed/28028029">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3210 href="http://dx.doi.org/10.1182/blood-2016-10-695940">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718201696"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e3219 class=n-a></a>Klampfl T, Gisslinger H, Harutyunyan AS, <i> et al.</i>: Somatic mutations of calreticulin in myeloproliferative neoplasms. <i>N Engl J Med.</i> 2013; <b>369</b>(25): 2379–90. <a target=xrefwindow id=d88552e3230 href="http://www.ncbi.nlm.nih.gov/pubmed/24325356">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3233 href="http://dx.doi.org/10.1056/NEJMoa1311347">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718201696">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718204849"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e3246 class=n-a></a>Nangalia J, Massie CE, Baxter EJ, <i> et al.</i>: Somatic <i>CALR</i> mutations in myeloproliferative neoplasms with nonmutated <i>JAK2</i>. <i>N Engl J Med.</i> 2013; <b>369</b>(25): 2391–405. <a target=xrefwindow id=d88552e3264 href="http://www.ncbi.nlm.nih.gov/pubmed/24325359">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3267 href="http://dx.doi.org/10.1056/NEJMoa1312542">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3270 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3966280">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718204849">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726014627"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e3284 class=n-a></a>Chachoua I, Pecquet C, El-Khoury M, <i> et al.</i>: Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. <i>Blood.</i> 2016; <b>127</b>(10): 1325–35. <a target=xrefwindow id=d88552e3295 href="http://www.ncbi.nlm.nih.gov/pubmed/26668133">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3298 href="http://dx.doi.org/10.1182/blood-2015-11-681932">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726014627">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725963335"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e3311 class=n-a></a>Marty C, Pecquet C, Nivarthi H, <i> et al.</i>: Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. <i>Blood.</i> 2016; <b>127</b>(10): 1317–24. <a target=xrefwindow id=d88552e3322 href="http://www.ncbi.nlm.nih.gov/pubmed/26608331">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3325 href="http://dx.doi.org/10.1182/blood-2015-11-679571">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725963335">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d88552e3338 class=n-a></a>Elf S, Abdelfattah NS, Chen E, <i> et al.</i>: Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. <i>Cancer Discov.</i> 2016; <b>6</b>(4): 368–81. <a target=xrefwindow id=d88552e3349 href="http://www.ncbi.nlm.nih.gov/pubmed/26951227">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3352 href="http://dx.doi.org/10.1158/2159-8290.CD-15-1434">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3356 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4851866">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726105715"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e3365 class=n-a></a>Araki M, Yang Y, Masubuchi N, <i> et al.</i>: Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. <i>Blood.</i> 2016; <b>127</b>(10): 1307–16. <a target=xrefwindow id=d88552e3376 href="http://www.ncbi.nlm.nih.gov/pubmed/26817954">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3379 href="http://dx.doi.org/10.1182/blood-2015-09-671172">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726105715">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d88552e3392 class=n-a></a>Lu X, Huang LJ, Lodish HF: Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. <i>J Biol Chem.</i> 2008; <b>283</b>(9): 5258–66. <a target=xrefwindow id=d88552e3400 href="http://www.ncbi.nlm.nih.gov/pubmed/18158285">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3403 href="http://dx.doi.org/10.1074/jbc.M707125200">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d88552e3412 class=n-a></a>Oh ST, Simonds EF, Jones C, <i> et al.</i>: Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. <i>Blood.</i> 2010; <b>116</b>(6): 988–92. <a target=xrefwindow id=d88552e3423 href="http://www.ncbi.nlm.nih.gov/pubmed/20404132">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3426 href="http://dx.doi.org/10.1182/blood-2010-02-270108">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3430 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2924231">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d88552e3440 class=n-a></a>Lasho TL, Pardanani A, Tefferi A: <i>LNK</i> mutations in <i>JAK2</i> mutation-negative erythrocytosis. <i>N Engl J Med.</i> 2010; <b>363</b>(12): 1189–90. <a target=xrefwindow id=d88552e3454 href="http://www.ncbi.nlm.nih.gov/pubmed/20843259">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3458 href="http://dx.doi.org/10.1056/NEJMc1006966">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726800485"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e3467 class=n-a></a>Rumi E, Harutyunyan AS, Pietra D, <i> et al.</i>: <i>LNK</i> mutations in familial myeloproliferative neoplasms. <i>Blood.</i> 2016; <b>128</b>(1): 144–5. <a target=xrefwindow id=d88552e3481 href="http://www.ncbi.nlm.nih.gov/pubmed/27216218">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3485 href="http://dx.doi.org/10.1182/blood-2016-04-711150">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726800485">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d88552e3498 class=n-a></a>Nangalia J, Grinfeld J, Green AR: Pathogenesis of Myeloproliferative Disorders. <i>Annu Rev Pathol.</i> 2016; <b>11</b>: 101–26. <a target=xrefwindow id=d88552e3506 href="http://www.ncbi.nlm.nih.gov/pubmed/27193452">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3509 href="http://dx.doi.org/10.1146/annurev-pathol-012615-044454">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d88552e3518 class=n-a></a>Viny AD, Levine RL: Genetics of myeloproliferative neoplasms. <i>Cancer J.</i> 2014; <b>20</b>(1): 61–5. <a target=xrefwindow id=d88552e3526 href="http://www.ncbi.nlm.nih.gov/pubmed/24445766">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3529 href="http://dx.doi.org/10.1097/PPO.0000000000000013">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3532 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3898518">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1163492"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e3541 class=n-a></a>Delhommeau F, Dupont S, Della Valle V, <i> et al.</i>: Mutation in <i>TET2</i> in myeloid cancers. <i>N Engl J Med.</i> 2009; <b>360</b>(22): 2289–301. <a target=xrefwindow id=d88552e3555 href="http://www.ncbi.nlm.nih.gov/pubmed/19474426">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3559 href="http://dx.doi.org/10.1056/NEJMoa0810069">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1163492">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d88552e3572 class=n-a></a>Saint-Martin C, Leroy G, Delhommeau F, <i> et al.</i>: Analysis of the ten-eleven translocation 2 (<i>TET2</i>) gene in familial myeloproliferative neoplasms. <i>Blood.</i> 2009; <b>114</b>(8): 1628–32. <a target=xrefwindow id=d88552e3586 href="http://www.ncbi.nlm.nih.gov/pubmed/19564637">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3590 href="http://dx.doi.org/10.1182/blood-2009-01-197525">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725352921"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e3600 class=n-a></a>Ortmann CA, Kent DG, Nangalia J, <i> et al.</i>: Effect of mutation order on myeloproliferative neoplasms. <i>N Engl J Med.</i> 2015; <b>372</b>(7): 601–12. <a target=xrefwindow id=d88552e3611 href="http://www.ncbi.nlm.nih.gov/pubmed/25671252">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3614 href="http://dx.doi.org/10.1056/NEJMoa1412098">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3618 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4660033">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725352921">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726500390"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e3631 class=n-a></a>Shimizu T, Kubovcakova L, Nienhold R, <i> et al.</i>: Loss of <i>Ezh2</i> synergizes with <i>JAK2</i>-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. <i>J Exp Med.</i> 2016; <b>213</b>(8): 1479–96. <a target=xrefwindow id=d88552e3649 href="http://www.ncbi.nlm.nih.gov/pubmed/27401344">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3652 href="http://dx.doi.org/10.1084/jem.20151136">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3655 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4986524">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726500390">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d88552e3668 class=n-a></a>Guglielmelli P, Lasho TL, Rotunno G, <i> et al.</i>: The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. <i>Leukemia.</i> 2014; <b>28</b>(9): 1804–10. <a target=xrefwindow id=d88552e3679 href="http://www.ncbi.nlm.nih.gov/pubmed/24549259">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3682 href="http://dx.doi.org/10.1038/leu.2014.76">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d88552e3691 class=n-a></a>Tefferi A, Vannucchi AM: Genetic Risk Assessment in Myeloproliferative Neoplasms. <i>Mayo Clin Proc.</i> 2017; <b>92</b>(8): 1283–90. <a target=xrefwindow id=d88552e3699 href="http://www.ncbi.nlm.nih.gov/pubmed/28778261">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3702 href="http://dx.doi.org/10.1016/j.mayocp.2017.06.002">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d88552e3711 class=n-a></a>Griesinger F, Hennig H, Hillmer F, <i> et al.</i>: A <i>BCR-JAK2</i> fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. <i>Genes Chromosomes Cancer.</i> 2005; <b>44</b>(3): 329–33. <a target=xrefwindow id=d88552e3725 href="http://www.ncbi.nlm.nih.gov/pubmed/16001431">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3729 href="http://dx.doi.org/10.1002/gcc.20235">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d88552e3738 class=n-a></a>Mark HF, Sotomayor EA, Nelson M, <i> et al.</i>: Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene. <i>Exp Mol Pathol.</i> 2006; <b>81</b>(3): 217–23. <a target=xrefwindow id=d88552e3749 href="http://www.ncbi.nlm.nih.gov/pubmed/16959246">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3752 href="http://dx.doi.org/10.1016/j.yexmp.2006.07.004">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d88552e3762 class=n-a></a>Peeters P, Raynaud SD, Cools J, <i> et al.</i>: Fusion of <i>TEL</i> the ETS-variant gene 6 (<i>ETV6</i>), to the receptor-associated kinase <i>JAK2</i> as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. <i>Blood.</i> 1997; <b>90</b>(7): 2535–40. <a target=xrefwindow id=d88552e3783 href="http://www.ncbi.nlm.nih.gov/pubmed/9326218">PubMed Abstract </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d88552e3792 class=n-a></a>Reiter A, Walz C, Watmore A, <i> et al.</i>: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses <i>PCM1</i> to <i>JAK2</i>. <i>Cancer Res.</i> 2005; <b>65</b>(7): 2662–7. <a target=xrefwindow id=d88552e3810 href="http://www.ncbi.nlm.nih.gov/pubmed/15805263">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3813 href="http://dx.doi.org/10.1158/0008-5472.CAN-04-4263">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d88552e3822 class=n-a></a>Maxson JE, Gotlib J, Pollyea DA, <i> et al.</i>: Oncogenic <i>CSF3R</i> mutations in chronic neutrophilic leukemia and atypical CML. <i>N Engl J Med.</i> 2013; <b>368</b>(19): 1781–90. <a target=xrefwindow id=d88552e3836 href="http://www.ncbi.nlm.nih.gov/pubmed/23656643">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3840 href="http://dx.doi.org/10.1056/NEJMoa1214514">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3843 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3730275">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d88552e3852 class=n-a></a>Patnaik MM, Tefferi A: Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. <i>Am J Hematol.</i> 2017; <b>92</b>(3): 297–310. <a target=xrefwindow id=d88552e3860 href="http://www.ncbi.nlm.nih.gov/pubmed/28188970">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3863 href="http://dx.doi.org/10.1002/ajh.24637">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3866 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5312971">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d88552e3875 class=n-a></a>Yoshida K, Toki T, Okuno Y, <i> et al.</i>: The landscape of somatic mutations in Down syndrome-related myeloid disorders. <i>Nat Genet.</i> 2013; <b>45</b>(11): 1293–9. <a target=xrefwindow id=d88552e3886 href="http://www.ncbi.nlm.nih.gov/pubmed/24056718">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3889 href="http://dx.doi.org/10.1038/ng.2759">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d88552e3898 class=n-a></a>Malinge S, Ragu C, Della-Valle V, <i> et al.</i>: Activating mutations in human acute megakaryoblastic leukemia. <i>Blood.</i> 2008; <b>112</b>(10): 4220–6. <a target=xrefwindow id=d88552e3909 href="http://www.ncbi.nlm.nih.gov/pubmed/18755984">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3912 href="http://dx.doi.org/10.1182/blood-2008-01-136366">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d88552e3922 class=n-a></a>Mullighan CG: The molecular genetic makeup of acute lymphoblastic leukemia. <i>Hematology Am Soc Hematol Educ Program.</i> 2012; <b>2012</b>: 389–96. <a target=xrefwindow id=d88552e3930 href="http://www.ncbi.nlm.nih.gov/pubmed/23233609">PubMed Abstract </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d88552e3939 class=n-a></a>Mullighan CG, Collins-Underwood JR, Phillips LA, <i> et al.</i>: Rearrangement of <i>CRLF2</i> in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. <i>Nat Genet.</i> 2009; <b>41</b>(11): 1243–6. <a target=xrefwindow id=d88552e3953 href="http://www.ncbi.nlm.nih.gov/pubmed/19838194">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3957 href="http://dx.doi.org/10.1038/ng.469">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3960 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2783810">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2753966"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e3969 class=n-a></a>Mullighan CG, Zhang J, Harvey RC, <i> et al.</i>: JAK mutations in high-risk childhood acute lymphoblastic leukemia. <i>Proc Natl Acad Sci U S A.</i> 2009; <b>106</b>(23): 9414–8. <a target=xrefwindow id=d88552e3980 href="http://www.ncbi.nlm.nih.gov/pubmed/19470474">PubMed Abstract </a> | <a target=xrefwindow id=d88552e3983 href="http://dx.doi.org/10.1073/pnas.0811761106">Publisher Full Text </a> | <a target=xrefwindow id=d88552e3987 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2695045">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2753966">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d88552e4000 class=n-a></a>Malinge S, Ben-Abdelali R, Settegrana C, <i> et al.</i>: Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. <i>Blood.</i> 2007; <b>109</b>(5): 2202–4. <a target=xrefwindow id=d88552e4011 href="http://www.ncbi.nlm.nih.gov/pubmed/17068151">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4014 href="http://dx.doi.org/10.1182/blood-2006-09-045963">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d88552e4023 class=n-a></a>Flex E, Petrangeli V, Stella L, <i> et al.</i>: Somatically acquired <i>JAK1</i> mutations in adult acute lymphoblastic leukemia. <i>J Exp Med.</i> 2008; <b>205</b>(4): 751–8. <a target=xrefwindow id=d88552e4037 href="http://www.ncbi.nlm.nih.gov/pubmed/18362173">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4041 href="http://dx.doi.org/10.1084/jem.20072182">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4044 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2292215">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d88552e4053 class=n-a></a>Hornakova T, Staerk J, Royer Y, <i> et al.</i>: Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. <i>J Biol Chem.</i> 2009; <b>284</b>(11): 6773–81. <a target=xrefwindow id=d88552e4064 href="http://www.ncbi.nlm.nih.gov/pubmed/19139102">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4067 href="http://dx.doi.org/10.1074/jbc.M807531200">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4071 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2652315">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d88552e4081 class=n-a></a>Tasian SK, Loh ML: Understanding the biology of <i>CRLF2</i>-overexpressing acute lymphoblastic leukemia. <i>Crit Rev Oncog.</i> 2011; <b>16</b>(1–2): 13–24. <a target=xrefwindow id=d88552e4092 href="http://www.ncbi.nlm.nih.gov/pubmed/22150304">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4095 href="http://dx.doi.org/10.1615/CritRevOncog.v16.i1-2.30">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4099 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4404310">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d88552e4108 class=n-a></a>Hertzberg L, Vendramini E, Ganmore I, <i> et al.</i>: Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of <i>CRLF2</i> is associated with mutated <i>JAK2</i>: a report from the International BFM Study Group. <i>Blood.</i> 2010; <b>115</b>(5): 1006–17. <a target=xrefwindow id=d88552e4126 href="http://www.ncbi.nlm.nih.gov/pubmed/19965641">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4129 href="http://dx.doi.org/10.1182/blood-2009-08-235408">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/10428956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e4138 class=n-a></a>Shochat C, Tal N, Bandapalli OR, <i> et al.</i>: Gain-of-function mutations in <i>interleukin-7 receptor</i>-α (<i>IL7R</i>) in childhood acute lymphoblastic leukemias. <i>J Exp Med.</i> 2011; <b>208</b>(5): 901–8. <a target=xrefwindow id=d88552e4156 href="http://www.ncbi.nlm.nih.gov/pubmed/21536738">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4159 href="http://dx.doi.org/10.1084/jem.20110580">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4162 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3092356">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/10428956">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d88552e4175 class=n-a></a>Iacobucci I, Li Y, Roberts KG, <i> et al.</i>: Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. <i>Cancer Cell.</i> 2016; <b>29</b>(2): 186–200. <a target=xrefwindow id=d88552e4186 href="http://www.ncbi.nlm.nih.gov/pubmed/26859458">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4189 href="http://dx.doi.org/10.1016/j.ccell.2015.12.013">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4193 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4750652">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d88552e4202 class=n-a></a>Neumann M, Greif PA, Baldus CD: Mutational landscape of adult ETP-ALL. <i>Oncotarget.</i> 2013; <b>4</b>(7): 954–5. <a target=xrefwindow id=d88552e4210 href="http://www.ncbi.nlm.nih.gov/pubmed/23807759">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4213 href="http://dx.doi.org/10.18632/oncotarget.1106">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4216 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3759672">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d88552e4225 class=n-a></a>Rui L, Emre NC, Kruhlak MJ, <i> et al.</i>: Cooperative epigenetic modulation by cancer amplicon genes. <i>Cancer Cell.</i> 2010; <b>18</b>(6): 590–605. <a target=xrefwindow id=d88552e4236 href="http://www.ncbi.nlm.nih.gov/pubmed/21156283">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4239 href="http://dx.doi.org/10.1016/j.ccr.2010.11.013">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4243 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3049192">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d88552e4253 class=n-a></a>Gunawardana J, Chan FC, Telenius A, <i> et al.</i>: Recurrent somatic mutations of <i>PTPN1</i> in primary mediastinal B cell lymphoma and Hodgkin lymphoma. <i>Nat Genet.</i> 2014; <b>46</b>(4): 329–35. <a target=xrefwindow id=d88552e4267 href="http://www.ncbi.nlm.nih.gov/pubmed/24531327">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4271 href="http://dx.doi.org/10.1038/ng.2900">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d88552e4280 class=n-a></a>Van Roosbroeck K, Cox L, Tousseyn T, <i> et al.</i>: <i>JAK2</i> rearrangements, including the novel <i>SEC31A-JAK2</i> fusion, are recurrent in classical Hodgkin lymphoma. <i>Blood.</i> 2011; <b>117</b>(15): 4056–64. <a target=xrefwindow id=d88552e4298 href="http://www.ncbi.nlm.nih.gov/pubmed/21325169">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4301 href="http://dx.doi.org/10.1182/blood-2010-06-291310">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d88552e4310 class=n-a></a>Bellanger D, Jacquemin V, Chopin M, <i> et al.</i>: Recurrent <i>JAK1</i> and <i>JAK3</i> somatic mutations in T-cell prolymphocytic leukemia. <i>Leukemia.</i> 2014; <b>28</b>(2): 417–9. <a target=xrefwindow id=d88552e4328 href="http://www.ncbi.nlm.nih.gov/pubmed/24048415">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4331 href="http://dx.doi.org/10.1038/leu.2013.271">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d88552e4340 class=n-a></a>Lee S, Park HY, Kang SY, <i> et al.</i>: Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. <i>Oncotarget.</i> 2015; <b>6</b>(19): 17764–76. <a target=xrefwindow id=d88552e4351 href="http://www.ncbi.nlm.nih.gov/pubmed/25980440">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4354 href="http://dx.doi.org/10.18632/oncotarget.3776">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4358 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4627344">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/8044956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e4367 class=n-a></a>Ngo VN, Young RM, Schmitz R, <i> et al.</i>: Oncogenically active <i>MYD88</i> mutations in human lymphoma. <i>Nature.</i> 2011; <b>470</b>(7332): 115–9. <a target=xrefwindow id=d88552e4381 href="http://www.ncbi.nlm.nih.gov/pubmed/21179087">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4385 href="http://dx.doi.org/10.1038/nature09671">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4388 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5024568">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/8044956">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d88552e4401 class=n-a></a>Plo I, Bellanné-Chantelot C, Mosca M, <i> et al.</i>: Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis. <i>Front Endocrinol (Lausanne).</i> 2017; <b>8</b>: 234. <a target=xrefwindow id=d88552e4412 href="http://www.ncbi.nlm.nih.gov/pubmed/28955303">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4415 href="http://dx.doi.org/10.3389/fendo.2017.00234">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4419 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5600916">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d88552e4429 class=n-a></a>Hong WJ, Gotlib J: Hereditary erythrocytosis, thrombocytosis and neutrophilia. <i>Best Pract Res Clin Haematol.</i> 2014; <b>27</b>(2): 95–106. <a target=xrefwindow id=d88552e4437 href="http://www.ncbi.nlm.nih.gov/pubmed/25189721">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4440 href="http://dx.doi.org/10.1016/j.beha.2014.07.002">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d88552e4449 class=n-a></a>Plo I, Zhang Y, Le Couédic JP, <i> et al.</i>: An activating mutation in the <i>CSF3R</i> gene induces a hereditary chronic neutrophilia. <i>J Exp Med.</i> 2009; <b>206</b>(8): 1701–7. <a target=xrefwindow id=d88552e4463 href="http://www.ncbi.nlm.nih.gov/pubmed/19620628">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4467 href="http://dx.doi.org/10.1084/jem.20090693">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4470 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2722170">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718236891"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e4479 class=n-a></a>Clark JD, Flanagan ME, Telliez JB: Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. <i>J Med Chem.</i> 2014; <b>57</b>(12): 5023–38. <a target=xrefwindow id=d88552e4487 href="http://www.ncbi.nlm.nih.gov/pubmed/24417533">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4490 href="http://dx.doi.org/10.1021/jm401490p">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718236891">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d88552e4503 class=n-a></a>Choi J, Ziga ED, Ritchey J, <i> et al.</i>: IFNγR signaling mediates alloreactive T-cell trafficking and GVHD. <i>Blood.</i> 2012; <b>120</b>(19): 4093–103. <a target=xrefwindow id=d88552e4514 href="http://www.ncbi.nlm.nih.gov/pubmed/22972985">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4517 href="http://dx.doi.org/10.1182/blood-2012-01-403196">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4521 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3496960">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d88552e4530 class=n-a></a>Leroy E, Constantinescu SN: Rethinking <i>JAK2</i> inhibition: towards novel strategies of more specific and versatile janus kinase inhibition. <i>Leukemia.</i> 2017; <b>31</b>(5): 1023–38. <a target=xrefwindow id=d88552e4541 href="http://www.ncbi.nlm.nih.gov/pubmed/28119526">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4544 href="http://dx.doi.org/10.1038/leu.2017.43">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d88552e4553 class=n-a></a>Bose P, Verstovsek S: JAK2 inhibitors for myeloproliferative neoplasms: what is next? <i>Blood.</i> 2017; <b>130</b>(2): 115–25. <a target=xrefwindow id=d88552e4561 href="http://www.ncbi.nlm.nih.gov/pubmed/28500170">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4564 href="http://dx.doi.org/10.1182/blood-2017-04-742288">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4567 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5510786">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d88552e4577 class=n-a></a>Tefferi A: Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. <i>N Engl J Med.</i> 2012; <b>366</b>(9): 844–6. <a target=xrefwindow id=d88552e4585 href="http://www.ncbi.nlm.nih.gov/pubmed/22375977">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4588 href="http://dx.doi.org/10.1056/NEJMe1115119">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d88552e4597 class=n-a></a>Schwartz DM, Bonelli M, Gadina M, <i> et al.</i>: Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. <i>Nat Rev Rheumatol.</i> 2016; <b>12</b>(1): 25–36. <a target=xrefwindow id=d88552e4608 href="http://www.ncbi.nlm.nih.gov/pubmed/26633291">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4611 href="http://dx.doi.org/10.1038/nrrheum.2015.167">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4615 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4688091">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731602772"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e4624 class=n-a></a>Kleppe M, Spitzer MH, Li S, <i> et al.</i>: Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis. <i>Cell Stem Cell.</i> 2017; <b>21</b>(4): 489–501.e7. <a target=xrefwindow id=d88552e4635 href="http://www.ncbi.nlm.nih.gov/pubmed/28965767">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4638 href="http://dx.doi.org/10.1016/j.stem.2017.08.011">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731602772">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d88552e4651 class=n-a></a>Tefferi A: JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. <i>Blood.</i> 2012; <b>119</b>(12): 2721–30. <a target=xrefwindow id=d88552e4659 href="http://www.ncbi.nlm.nih.gov/pubmed/22279053">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4662 href="http://dx.doi.org/10.1182/blood-2011-11-395228">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d88552e4671 class=n-a></a>Zhang Q, Zhang Y, Diamond S, <i> et al.</i>: The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. <i>Drug Metab Dispos.</i> 2014; <b>42</b>(10): 1656–62. <a target=xrefwindow id=d88552e4682 href="http://www.ncbi.nlm.nih.gov/pubmed/25063672">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4685 href="http://dx.doi.org/10.1124/dmd.114.058883">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d88552e4694 class=n-a></a>Fleischmann R: Tofacitinib in the treatment of active rheumatoid arthritis in adults. <i>Immunotherapy.</i> 2018; <b>10</b>(1): 39–56. <a target=xrefwindow id=d88552e4702 href="http://www.ncbi.nlm.nih.gov/pubmed/29043892">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4705 href="http://dx.doi.org/10.2217/imt-2017-0118">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d88552e4715 class=n-a></a>Koppikar P, Bhagwat N, Kilpivaara O, <i> et al.</i>: Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. <i>Nature.</i> 2012; <b>489</b>(7414): 155–9. <a target=xrefwindow id=d88552e4726 href="http://www.ncbi.nlm.nih.gov/pubmed/22820254">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4729 href="http://dx.doi.org/10.1038/nature11303">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4733 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3991463">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d88552e4742 class=n-a></a>Meyer SC, Levine RL: Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. <i>Clin Cancer Res.</i> 2014; <b>20</b>(8): 2051–9. <a target=xrefwindow id=d88552e4750 href="http://www.ncbi.nlm.nih.gov/pubmed/24583800">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4753 href="http://dx.doi.org/10.1158/1078-0432.CCR-13-0279">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4756 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3990645">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d88552e4765 class=n-a></a>Blanc J, Geney R, Menet C: Type II kinase inhibitors: an opportunity in cancer for rational design. <i>Anticancer Agents Med Chem.</i> 2013; <b>13</b>(5): 731–47. <a target=xrefwindow id=d88552e4773 href="http://www.ncbi.nlm.nih.gov/pubmed/23094911">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4776 href="http://dx.doi.org/10.2174/1871520611313050008">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725638177"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e4785 class=n-a></a>Meyer SC, Keller MD, Chiu S, <i> et al.</i>: CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. <i>Cancer Cell.</i> 2015; <b>28</b>(1): 15–28. <a target=xrefwindow id=d88552e4796 href="http://www.ncbi.nlm.nih.gov/pubmed/26175413">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4799 href="http://dx.doi.org/10.1016/j.ccell.2015.06.006">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4803 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4503933">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725638177">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725638176"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e4816 class=n-a></a>Wu SC, Li LS, Kopp N, <i> et al.</i>: Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell.</i> 2015; <b>28</b>(1): 29–41. <a target=xrefwindow id=d88552e4827 href="http://www.ncbi.nlm.nih.gov/pubmed/26175414">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4830 href="http://dx.doi.org/10.1016/j.ccell.2015.06.005">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4834 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4505625">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725638176">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d88552e4847 class=n-a></a>Harrison C, Kiladjian JJ, Al-Ali HK, <i> et al.</i>: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. <i>N Engl J Med.</i> 2012; <b>366</b>(9): 787–98. <a target=xrefwindow id=d88552e4858 href="http://www.ncbi.nlm.nih.gov/pubmed/22375970">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4861 href="http://dx.doi.org/10.1056/NEJMoa1110556">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725330328"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e4871 class=n-a></a>Vannucchi AM, Kiladjian JJ, Griesshammer M, <i> et al.</i>: Ruxolitinib versus standard therapy for the treatment of polycythemia vera. <i>N Engl J Med.</i> 2015; <b>372</b>(5): 426–35. <a target=xrefwindow id=d88552e4882 href="http://www.ncbi.nlm.nih.gov/pubmed/25629741">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4885 href="http://dx.doi.org/10.1056/NEJMoa1409002">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4889 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4358820">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725330328">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d88552e4902 class=n-a></a>Verstovsek S, Mesa RA, Gotlib J, <i> et al.</i>: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. <i>N Engl J Med.</i> 2012; <b>366</b>(9): 799–807. <a target=xrefwindow id=d88552e4913 href="http://www.ncbi.nlm.nih.gov/pubmed/22375971">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4916 href="http://dx.doi.org/10.1056/NEJMoa1110557">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4920 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4822164">Free Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d88552e4929 class=n-a></a>Eghtedar A, Verstovsek S, Estrov Z, <i> et al.</i>: Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. <i>Blood.</i> 2012; <b>119</b>(20): 4614–8. <a target=xrefwindow id=d88552e4940 href="http://www.ncbi.nlm.nih.gov/pubmed/22422826">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4943 href="http://dx.doi.org/10.1182/blood-2011-12-400051">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4947 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4081383">Free Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725777074"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e4956 class=n-a></a>Hurwitz HI, Uppal N, Wagner SA, <i> et al.</i>: Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. <i>J Clin Oncol.</i> 2015; <b>33</b>(34): 4039–47. <a target=xrefwindow id=d88552e4967 href="http://www.ncbi.nlm.nih.gov/pubmed/26351344">PubMed Abstract </a> | <a target=xrefwindow id=d88552e4970 href="http://dx.doi.org/10.1200/JCO.2015.61.4578">Publisher Full Text </a> | <a target=xrefwindow id=d88552e4974 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5089161">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725777074">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725689454"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e4987 class=n-a></a>Zeiser R, Burchert A, Lengerke C, <i> et al.</i>: Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. <i>Leukemia.</i> 2015; <b>29</b>(10): 2062–8. <a target=xrefwindow id=d88552e4998 href="http://www.ncbi.nlm.nih.gov/pubmed/26228813">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5001 href="http://dx.doi.org/10.1038/leu.2015.212">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5005 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4854652">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725689454">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d88552e5018 class=n-a></a>Punwani N, Scherle P, Flores R, <i> et al.</i>: Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. <i>J Am Acad Dermatol.</i> 2012; <b>67</b>(4): 658–64. <a target=xrefwindow id=d88552e5029 href="http://www.ncbi.nlm.nih.gov/pubmed/22281165">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5032 href="http://dx.doi.org/10.1016/j.jaad.2011.12.018">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d88552e5042 class=n-a></a>Mackay-Wiggan J, Jabbari A, Nguyen N, <i> et al.</i>: Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. <i>JCI Insight.</i> 2016; <b>1</b>(15): e89790. <a target=xrefwindow id=d88552e5053 href="http://www.ncbi.nlm.nih.gov/pubmed/27699253">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5056 href="http://dx.doi.org/10.1172/jci.insight.89790">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5060 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5033756">Free Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726695907"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e5069 class=n-a></a>Harris JE, Rashighi M, Nguyen N, <i> et al.</i>: Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). <i>J Am Acad Dermatol.</i> 2016; <b>74</b>(2): 370–1. <a target=xrefwindow id=d88552e5080 href="http://www.ncbi.nlm.nih.gov/pubmed/26685721">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5083 href="http://dx.doi.org/10.1016/j.jaad.2015.09.073">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5087 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4718770">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726695907">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d88552e5100 class=n-a></a>Mesa RA, Kiladjian JJ, Catalano JV, <i> et al.</i>: SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. <i>J Clin Oncol.</i> 2017; <b>35</b>(34): 3844–50. <a target=xrefwindow id=d88552e5111 href="http://www.ncbi.nlm.nih.gov/pubmed/28930494">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5114 href="http://dx.doi.org/10.1200/JCO.2017.73.4418">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d88552e5123 class=n-a></a>Verstovsek S, Courby S, Griesshammer M, <i> et al.</i>: A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. <i>Leuk Res.</i> 2017; <b>60</b>: 11–7. <a target=xrefwindow id=d88552e5134 href="http://www.ncbi.nlm.nih.gov/pubmed/28622623">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5137 href="http://dx.doi.org/10.1016/j.leukres.2017.05.002">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d88552e5146 class=n-a></a>Verstovsek S, Hoffman R, Mascarenhas J, <i> et al.</i>: A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. <i>Leuk Res.</i> 2015; <b>39</b>(2): 157–63. <a target=xrefwindow id=d88552e5157 href="http://www.ncbi.nlm.nih.gov/pubmed/25530567">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5160 href="http://dx.doi.org/10.1016/j.leukres.2014.11.018">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d88552e5169 class=n-a></a>Suryani S, Bracken LS, Harvey RC, <i> et al.</i>: Evaluation of the <i>in vitro</i> and <i>in vivo</i> efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. <i>Mol Cancer Ther.</i> 2015; <b>14</b>(2): 364–74. <a target=xrefwindow id=d88552e5187 href="http://www.ncbi.nlm.nih.gov/pubmed/25504635">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5190 href="http://dx.doi.org/10.1158/1535-7163.MCT-14-0647">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5193 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4326541">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d88552e5203 class=n-a></a>Plimack ER, Lorusso PM, McCoon P, <i> et al.</i>: AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. <i>Oncologist.</i> 2013; <b>18</b>(7): 819–20. <a target=xrefwindow id=d88552e5214 href="http://www.ncbi.nlm.nih.gov/pubmed/23847256">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5217 href="http://dx.doi.org/10.1634/theoncologist.2013-0198">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5221 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3720635">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d88552e5230 class=n-a></a>Keystone EC, Taylor PC, Tanaka Y, <i> et al.</i>: Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. <i>Ann Rheum Dis.</i> 2017; <b>76</b>(11): 1853–61. <a target=xrefwindow id=d88552e5241 href="http://www.ncbi.nlm.nih.gov/pubmed/28798049">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5244 href="http://dx.doi.org/10.1136/annrheumdis-2017-211259">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5248 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5705852">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d88552e5257 class=n-a></a>Papp KA, Menter MA, Raman M, <i> et al.</i>: A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. <i>Br J Dermatol.</i> 2016; <b>174</b>(6): 1266–76. <a target=xrefwindow id=d88552e5268 href="http://www.ncbi.nlm.nih.gov/pubmed/26800231">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5271 href="http://dx.doi.org/10.1111/bjd.14403">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d88552e5280 class=n-a></a>NICE issues positive recommendation for XELJANZ®▼(tofacitinib citrate) as a new treatment option for adults with severe rheumatoid arthritis. <i>Rheumatology (Oxford).</i> 2017; <b>56</b>(12): e49. <a target=xrefwindow id=d88552e5288 href="http://www.ncbi.nlm.nih.gov/pubmed/29040714">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5291 href="http://dx.doi.org/10.1093/rheumatology/kex407">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d88552e5300 class=n-a></a>Panés J, Sandborn WJ, Schreiber S, <i> et al.</i>: Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. <i>Gut.</i> 2017; <b>66</b>(6): 1049–59. <a target=xrefwindow id=d88552e5311 href="http://www.ncbi.nlm.nih.gov/pubmed/28209624">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5314 href="http://dx.doi.org/10.1136/gutjnl-2016-312735">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5318 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5532457">Free Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d88552e5327 class=n-a></a>Feldman SR, Thaçi D, Gooderham M, <i> et al.</i>: Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. <i>J Am Acad Dermatol.</i> 2016; <b>75</b>(6): 1162–1170.e3. <a target=xrefwindow id=d88552e5338 href="http://www.ncbi.nlm.nih.gov/pubmed/27692733">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5341 href="http://dx.doi.org/10.1016/j.jaad.2016.07.040">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d88552e5351 class=n-a></a>Vu M, Heyes C, Robertson SJ, <i> et al.</i>: Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo. <i>Clin Exp Dermatol.</i> 2017; <b>42</b>(8): 942–4. <a target=xrefwindow id=d88552e5362 href="http://www.ncbi.nlm.nih.gov/pubmed/29034491">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5365 href="http://dx.doi.org/10.1111/ced.13290">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731255028"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e5374 class=n-a></a>Verstovsek S, Mesa RA, Salama ME, <i> et al.</i>: A phase 1 study of the Janus kinase 2 <i>(JAK2)</i><sup>V617F</sup> inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. <i>Leuk Res.</i> 2017; <b>61</b>: 89–95. <a target=xrefwindow id=d88552e5390 href="http://www.ncbi.nlm.nih.gov/pubmed/28934680">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5394 href="http://dx.doi.org/10.1016/j.leukres.2017.08.010">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731255028">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d88552e5407 class=n-a></a>Verstovsek S, Tam CS, Wadleigh M, <i> et al.</i>: Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. <i>Leuk Res.</i> 2014; <b>38</b>(3): 316–22. <a target=xrefwindow id=d88552e5418 href="http://www.ncbi.nlm.nih.gov/pubmed/24374145">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5421 href="http://dx.doi.org/10.1016/j.leukres.2013.12.006">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5425 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4414320">Free Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d88552e5434 class=n-a></a>Baffert F, Régnier CH, De Pover A, <i> et al.</i>: Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. <i>Mol Cancer Ther.</i> 2010; <b>9</b>(7): 1945–55. <a target=xrefwindow id=d88552e5445 href="http://www.ncbi.nlm.nih.gov/pubmed/20587663">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5448 href="http://dx.doi.org/10.1158/1535-7163.MCT-10-0053">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d88552e5457 class=n-a></a>Nakaya Y, Shide K, Niwa T, <i> et al.</i>: Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. <i>Blood Cancer J.</i> 2011; <b>1</b>(7): e29. <a target=xrefwindow id=d88552e5468 href="http://www.ncbi.nlm.nih.gov/pubmed/22829185">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5471 href="http://dx.doi.org/10.1038/bcj.2011.29">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5475 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3255248">Free Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d88552e5484 class=n-a></a>Mesa RA, Vannucchi AM, Mead A, <i> et al.</i>: Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. <i>Lancet Haematol.</i> 2017; <b>4</b>(5): e225–e236. <a target=xrefwindow id=d88552e5495 href="http://www.ncbi.nlm.nih.gov/pubmed/28336242">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5498 href="http://dx.doi.org/10.1016/S2352-3026(17)30027-3">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d88552e5508 class=n-a></a>Mascarenhas J, Hoffman R, Talpaz M, <i> et al.</i>: Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) versus Best Available Therapy (BAT), including Ruxolitinib (RUX), in Patients with Myelofibrosis and Platelet Counts &lt;100,000/μL. <i>Blood, 58th AmericanSociety of Hematology (ASH) Annual Meeting, 3–6 Dec 2016</i>, San Diego. 2016. <a target=xrefwindow id=d88552e5516 href="http://www.ctibiopharma.com/wp-content/uploads/2016/12/Mascarenhas_PERSIST-2_ASH_4Dec2016-FINALf.pdf">Reference Source</a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d88552e5525 class=n-a></a>Stump KL, Lu LD, Dobrzanski P, <i> et al.</i>: A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. <i>Arthritis Res Ther.</i> 2011; <b>13</b>(2): R68. <a target=xrefwindow id=d88552e5536 href="http://www.ncbi.nlm.nih.gov/pubmed/21510883">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5539 href="http://dx.doi.org/10.1186/ar3329">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5543 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3132063">Free Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d88552e5552 class=n-a></a>Ringel F, Kaeda J, Schwarz M, <i> et al.</i>: Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines. <i>Acta Haematol.</i> 2014; <b>132</b>(1): 75–86. <a target=xrefwindow id=d88552e5563 href="http://www.ncbi.nlm.nih.gov/pubmed/24504330">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5566 href="http://dx.doi.org/10.1159/000356784">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d88552e5575 class=n-a></a>Pardanani A, Hood J, Lasho T, <i> et al.</i>: TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. <i>Leukemia.</i> 2007; <b>21</b>(8): 1658–68. <a target=xrefwindow id=d88552e5586 href="http://www.ncbi.nlm.nih.gov/pubmed/17541402">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5589 href="http://dx.doi.org/10.1038/sj.leu.2404750">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d88552e5598 class=n-a></a>Pardanani A, Tefferi A, Jamieson C, <i> et al.</i>: A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. <i>Blood Cancer J.</i> 2015; <b>5</b>(8): e335. <a target=xrefwindow id=d88552e5609 href="http://www.ncbi.nlm.nih.gov/pubmed/26252788">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5612 href="http://dx.doi.org/10.1038/bcj.2015.63">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5616 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4558588">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d88552e5625 class=n-a></a>Vanhoutte F, Mazur M, Voloshyn O, <i> et al.</i>: Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. <i>Arthritis Rheumatol.</i> 2017; <b>69</b>(10): 1949–59. <a target=xrefwindow id=d88552e5636 href="http://www.ncbi.nlm.nih.gov/pubmed/28622463">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5639 href="http://dx.doi.org/10.1002/art.40186">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5643 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5656813">Free Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d88552e5653 class=n-a></a>Vermeire S, Schreiber S, Petryka R, <i> et al.</i>: Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. <i>Lancet.</i> 2017; <b>389</b>(10066): 266–75. <a target=xrefwindow id=d88552e5664 href="http://www.ncbi.nlm.nih.gov/pubmed/27988142">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5667 href="http://dx.doi.org/10.1016/S0140-6736(16)32537-5">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727869572"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e5676 class=n-a></a>Baker KF, Isaacs JD: Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? <i>Ann Rheum Dis.</i> 2017; pii: annrheumdis-2017-211555. <a target=xrefwindow id=d88552e5681 href="http://www.ncbi.nlm.nih.gov/pubmed/28765121">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5684 href="http://dx.doi.org/10.1136/annrheumdis-2017-211555">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727869572">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726901360"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e5697 class=n-a></a>Mascarenhas JO, Talpaz M, Gupta V, <i> et al.</i>: Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. <i>Haematologica.</i> 2017; <b>102</b>(2): 327–35. <a target=xrefwindow id=d88552e5708 href="http://www.ncbi.nlm.nih.gov/pubmed/27789678">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5711 href="http://dx.doi.org/10.3324/haematol.2016.151126">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5715 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5286940">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726901360">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d88552e5728 class=n-a></a>Bissonnette R, Luchi M, Fidelus-Gort R, <i> et al.</i>: A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. <i>J Dermatolog Treat.</i> 2016; <b>27</b>(4): 332–8. <a target=xrefwindow id=d88552e5739 href="http://www.ncbi.nlm.nih.gov/pubmed/26769332">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5742 href="http://dx.doi.org/10.3109/09546634.2015.1115819">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d88552e5751 class=n-a></a>Schmieder GJ, Draelos ZD, Pariser DM, <i> et al.</i>: Efficacy and safety of the Janus Kinase 1 inhibitor PF-04965842 in patients with moderate to severe psoriasis: phase 2, randomized, double-blind, placebo-controlled study. <i>Br J Dermatol.</i> 2017. <a target=xrefwindow id=d88552e5759 href="http://www.ncbi.nlm.nih.gov/pubmed/28949012">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5762 href="http://dx.doi.org/10.1111/bjd.16004">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d88552e5771 class=n-a></a>Klünder B, Mohamed MF, Othman AA: Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials. <i>Clin Pharmacokinet.</i> 2017; 1–12. <a target=xrefwindow id=d88552e5776 href="http://www.ncbi.nlm.nih.gov/pubmed/29076110">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5779 href="http://dx.doi.org/10.1007/s40262-017-0605-6">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d88552e5789 class=n-a></a>Fleischmann RM, Damjanov NS, Kivitz AJ, <i> et al.</i>: A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. <i>Arthritis Rheumatol.</i> 2015; <b>67</b>(2): 334–43. <a target=xrefwindow id=d88552e5800 href="http://www.ncbi.nlm.nih.gov/pubmed/25385260">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5803 href="http://dx.doi.org/10.1002/art.38949">Publisher Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d88552e5812 class=n-a></a>Uckun FM, Roers BA, Waurzyniak B, <i> et al.</i>: Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. <i>Blood.</i> 2002; <b>99</b>(11): 4192–9. <a target=xrefwindow id=d88552e5823 href="http://www.ncbi.nlm.nih.gov/pubmed/12010825">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5826 href="http://dx.doi.org/10.1182/blood.V99.11.4192">Publisher Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725364136"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e5835 class=n-a></a>Papp K, Pariser D, Catlin M, <i> et al.</i>: A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. <i>Br J Dermatol.</i> 2015; <b>173</b>(3): 767–76. <a target=xrefwindow id=d88552e5846 href="http://www.ncbi.nlm.nih.gov/pubmed/25704750">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5849 href="http://dx.doi.org/10.1111/bjd.13745">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725364136">F1000 Recommendation</a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d88552e5862 class=n-a></a>Takeuchi T, Tanaka Y, Iwasaki M, <i> et al.</i>: Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. <i>Ann Rheum Dis.</i> 2016; <b>75</b>(6): 1057–64. <a target=xrefwindow id=d88552e5873 href="http://www.ncbi.nlm.nih.gov/pubmed/26672064">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5876 href="http://dx.doi.org/10.1136/annrheumdis-2015-208279">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5880 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4893099">Free Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d88552e5889 class=n-a></a>Lipka DB, Hoffmann LS, Heidel F, <i> et al.</i>: LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in <i>JAK2V617F</i>-positive cells. <i>Mol Cancer Ther.</i> 2008; <b>7</b>(5): 1176–84. <a target=xrefwindow id=d88552e5903 href="http://www.ncbi.nlm.nih.gov/pubmed/18483305">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5907 href="http://dx.doi.org/10.1158/1535-7163.MCT-07-2215">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d88552e5916 class=n-a></a>Jatiani SS, Cosenza SC, Reddy MV, <i> et al.</i>: A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. <i>Genes Cancer.</i> 2010; <b>1</b>(4): 331–45. <a target=xrefwindow id=d88552e5927 href="http://www.ncbi.nlm.nih.gov/pubmed/20717479">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5930 href="http://dx.doi.org/10.1177/1947601910371337">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5934 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2921666">Free Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d88552e5944 class=n-a></a>Al-Ali HK, Griesshammer M, Le Coutre P, <i> et al.</i>: Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. <i>Haematologica.</i> 2016; <b>101</b>(9): 1065–73. <a target=xrefwindow id=d88552e5955 href="http://www.ncbi.nlm.nih.gov/pubmed/27247324">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5958 href="http://dx.doi.org/10.3324/haematol.2016.143677">Publisher Full Text </a> | <a target=xrefwindow id=d88552e5962 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5060023">Free Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727072748"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e5971 class=n-a></a>Passamonti F, Griesshammer M, Palandri F, <i> et al.</i>: Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. <i>Lancet Oncol.</i> 2017; <b>18</b>(1): 88–99. <a target=xrefwindow id=d88552e5982 href="http://www.ncbi.nlm.nih.gov/pubmed/27916398">PubMed Abstract </a> | <a target=xrefwindow id=d88552e5985 href="http://dx.doi.org/10.1016/S1470-2045(16)30558-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727072748">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728372277"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e5998 class=n-a></a>Harrison CN, Mead AJ, Panchal A, <i> et al.</i>: Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. <i>Blood.</i> 2017; <b>130</b>(17): 1889–97. <a target=xrefwindow id=d88552e6009 href="http://www.ncbi.nlm.nih.gov/pubmed/29074595">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6012 href="http://dx.doi.org/10.1182/blood-2017-05-785790">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728372277">F1000 Recommendation</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732243666"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6025 class=n-a></a>Verstovsek S, Passamonti F, Rambaldi A, <i> et al.</i>: Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. <i>Blood.</i> 2017; <b>130</b>(15): 1768–71. <a target=xrefwindow id=d88552e6036 href="http://www.ncbi.nlm.nih.gov/pubmed/28827411">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6039 href="http://dx.doi.org/10.1182/blood-2017-02-765032">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6043 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5639482">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732243666">F1000 Recommendation</a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d88552e6056 class=n-a></a>Curto-Garcia N, Harrison CN: An updated review of the <i>JAK1/2</i> inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms. <i>Future Oncol.</i> 2017; <b>14</b>(2): 137–150. <a target=xrefwindow id=d88552e6067 href="http://www.ncbi.nlm.nih.gov/pubmed/29056075">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6070 href="http://dx.doi.org/10.2217/fon-2017-0298">Publisher Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d88552e6079 class=n-a></a>Saeed I, McLornan D, Harrison CN: Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. <i>Expert Rev Hematol.</i> 2017; <b>10</b>(7): 617–25. <a target=xrefwindow id=d88552e6087 href="http://www.ncbi.nlm.nih.gov/pubmed/28571503">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6090 href="http://dx.doi.org/10.1080/17474086.2017.1337507">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725418143"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6100 class=n-a></a>Schönberg K, Rudolph J, Vonnahme M, <i> et al.</i>: JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. <i>Cancer Res.</i> 2015; <b>75</b>(11): 2187–99. <a target=xrefwindow id=d88552e6111 href="http://www.ncbi.nlm.nih.gov/pubmed/25832652">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6114 href="http://dx.doi.org/10.1158/0008-5472.CAN-14-3198">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725418143">F1000 Recommendation</a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727083898"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6127 class=n-a></a>Curran SA, Shyer JA, St Angelo ET, <i> et al.</i>: Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade. <i>Cancer Immunol Res.</i> 2017; <b>5</b>(1): 52–60. <a target=xrefwindow id=d88552e6138 href="http://www.ncbi.nlm.nih.gov/pubmed/27923824">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6141 href="http://dx.doi.org/10.1158/2326-6066.CIR-16-0233">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6145 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5335862">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727083898">F1000 Recommendation</a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732417928"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6158 class=n-a></a>Verstovsek S, Gotlib J, Mesa RA, <i> et al.</i>: Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. <i>J Hematol Oncol.</i> 2017; <b>10</b>(1): 156. <a target=xrefwindow id=d88552e6169 href="http://www.ncbi.nlm.nih.gov/pubmed/28962635">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6172 href="http://dx.doi.org/10.1186/s13045-017-0527-7">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6176 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5622445">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732417928">F1000 Recommendation</a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d88552e6189 class=n-a></a>Pardanani A, Abdelrahman RA, Finke C, <i> et al.</i>: Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. <i>Leukemia.</i> 2015; <b>29</b>(3): 741–4. <a target=xrefwindow id=d88552e6200 href="http://www.ncbi.nlm.nih.gov/pubmed/25322686">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6203 href="http://dx.doi.org/10.1038/leu.2014.306">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6207 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4360208">Free Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d88552e6216 class=n-a></a>Gupta V, Mesa RA, Deininger MW, <i> et al.</i>: A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. <i>Haematologica.</i> 2017; <b>102</b>(1): 94–102. <a target=xrefwindow id=d88552e6227 href="http://www.ncbi.nlm.nih.gov/pubmed/27634203">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6230 href="http://dx.doi.org/10.3324/haematol.2016.148924">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6234 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5210237">Free Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d88552e6243 class=n-a></a>Pardanani A, Gotlib JR, Gupta V, <i> et al.</i>: Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. <i>Blood.</i> 2013; <b>122</b>(21): 108. <a target=xrefwindow id=d88552e6254 href="https://www.researchgate.net/publication/296046286_Update_On_The_Long-Term_Efficacy_and_Safety_Of_Momelotinib_a_JAK1_and_JAK2_Inhibitor_For_The_Treatment_Of_Myelofibrosis">Reference Source</a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727294475"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6264 class=n-a></a>Asshoff M, Petzer V, Warr MR, <i> et al.</i>: Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. <i>Blood.</i> 2017; <b>129</b>(13): 1823–30. <a target=xrefwindow id=d88552e6275 href="http://www.ncbi.nlm.nih.gov/pubmed/28188131">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6278 href="http://dx.doi.org/10.1182/blood-2016-09-740092">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6282 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5693322">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727294475">F1000 Recommendation</a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726596461"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6295 class=n-a></a>Verstovsek S, Talpaz M, Ritchie E, <i> et al.</i>: A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. <i>Leukemia.</i> 2017; <b>31</b>(2): 393–402. <a target=xrefwindow id=d88552e6306 href="http://www.ncbi.nlm.nih.gov/pubmed/27479177">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6309 href="http://dx.doi.org/10.1038/leu.2016.215">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6313 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5292677">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726596461">F1000 Recommendation</a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727104381"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6326 class=n-a></a>Verstovsek S, Odenike O, Singer JW, <i> et al.</i>: Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. <i>J Hematol Oncol.</i> 2016; <b>9</b>(1): 137. <a target=xrefwindow id=d88552e6337 href="http://www.ncbi.nlm.nih.gov/pubmed/27931243">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6340 href="http://dx.doi.org/10.1186/s13045-016-0367-x">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6344 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5146859">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727104381">F1000 Recommendation</a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d88552e6357 class=n-a></a>BioPharma C: CTI BioPharma Provides Update On Clinical Hold Of Investigational Agent Pacritinib And New Drug Application In U.S. 2016. <a target=xrefwindow id=d88552e6359 href="http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&amp;p=RssLanding&amp;cat=news&amp;id=2137027">Reference Source</a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d88552e6368 class=n-a></a>PR Newswire CB: CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib. 2017. <a target=xrefwindow id=d88552e6370 href="http://www.prnewswire.com/news-releases/cti-biopharma-announces-removal-of-full-clinical-hold-on-pacritinib-300386115.html.">Reference Source</a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727712072"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6379 class=n-a></a>Harrison CN, Schaap N, Vannucchi AM, <i> et al.</i>: Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. <i>Lancet Haematol.</i> 2017; <b>4</b>(7): e317–e324. <a target=xrefwindow id=d88552e6390 href="http://www.ncbi.nlm.nih.gov/pubmed/28602585">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6393 href="http://dx.doi.org/10.1016/S2352-3026(17)30088-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727712072">F1000 Recommendation</a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725782342"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6407 class=n-a></a>Jamieson C, Hasserjian R, Gotlib J, <i> et al.</i>: Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. <i>J Transl Med.</i> 2015; <b>13</b>: 294. <a target=xrefwindow id=d88552e6418 href="http://www.ncbi.nlm.nih.gov/pubmed/26357842">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6421 href="http://dx.doi.org/10.1186/s12967-015-0644-4">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6425 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4566296">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725782342">F1000 Recommendation</a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d88552e6438 class=n-a></a>Pardanani A, Harrison C, Cortes JE, <i> et al.</i>: Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. <i>JAMA Oncol.</i> 2015; <b>1</b>(5): 643–51. <a target=xrefwindow id=d88552e6449 href="http://www.ncbi.nlm.nih.gov/pubmed/26181658">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6452 href="http://dx.doi.org/10.1001/jamaoncol.2015.1590">Publisher Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727229986"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6461 class=n-a></a>Hazell AS, Afadlal S, Cheresh DA, <i> et al.</i>: Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke's encephalopathy. <i>Neurosci Lett.</i> 2017; <b>642</b>: 163–7. <a target=xrefwindow id=d88552e6472 href="http://www.ncbi.nlm.nih.gov/pubmed/28109775">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6475 href="http://dx.doi.org/10.1016/j.neulet.2017.01.041">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727229986">F1000 Recommendation</a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d88552e6488 class=n-a></a>Buchert M, Burns CJ, Ernst M: Targeting JAK kinase in solid tumors: emerging opportunities and challenges. <i>Oncogene.</i> 2016; <b>35</b>(8): 939–51. <a target=xrefwindow id=d88552e6496 href="http://www.ncbi.nlm.nih.gov/pubmed/25982279">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6499 href="http://dx.doi.org/10.1038/onc.2015.150">Publisher Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726728915"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6508 class=n-a></a>Yu HA, Perez L, Chang Q, <i> et al.</i>: A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with <i>EGFR</i>-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. <i>J Thorac Oncol.</i> 2017; <b>12</b>(1): 102–9. <a target=xrefwindow id=d88552e6522 href="http://www.ncbi.nlm.nih.gov/pubmed/27613527">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6526 href="http://dx.doi.org/10.1016/j.jtho.2016.08.140">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6529 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5552054">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726728915">F1000 Recommendation</a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d88552e6542 class=n-a></a>Dao KT, Solti MB, Maxson JE, <i> et al.</i>: Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. <i>Leuk Res Rep.</i> 2014; <b>3</b>(2): 67–9. <a target=xrefwindow id=d88552e6553 href="http://www.ncbi.nlm.nih.gov/pubmed/25180155">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6556 href="http://dx.doi.org/10.1016/j.lrr.2014.07.002">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6560 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4145163">Free Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d88552e6570 class=n-a></a>Lierman E, Selleslag D, Smits S, <i> et al.</i>: Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/<i>PCM1-JAK2</i>-positive chronic eosinophilic leukemia. <i>Blood.</i> 2012; <b>120</b>(7): 1529–31. <a target=xrefwindow id=d88552e6584 href="http://www.ncbi.nlm.nih.gov/pubmed/22899477">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6588 href="http://dx.doi.org/10.1182/blood-2012-06-433821">Publisher Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d88552e6597 class=n-a></a>Rumi E, Milosevic JD, Selleslag D, <i> et al.</i>: Efficacy of ruxolitinib in myeloid neoplasms with <i>PCM1-JAK2</i> fusion gene. <i>Ann Hematol.</i> 2015; <b>94</b>(11): 1927–8. <a target=xrefwindow id=d88552e6611 href="http://www.ncbi.nlm.nih.gov/pubmed/26202607">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6615 href="http://dx.doi.org/10.1007/s00277-015-2451-7">Publisher Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d88552e6624 class=n-a></a>Schwaab J, Knut M, Haferlach C, <i> et al.</i>: Limited duration of complete remission on ruxolitinib in myeloid neoplasms with <i>PCM1-JAK2</i> and <i>BCR-JAK2</i> fusion genes. <i>Ann Hematol.</i> 2015; <b>94</b>(2): 233–8. <a target=xrefwindow id=d88552e6642 href="http://www.ncbi.nlm.nih.gov/pubmed/25260694">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6645 href="http://dx.doi.org/10.1007/s00277-014-2221-y">Publisher Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d88552e6654 class=n-a></a>Welsch K, Holstein J, Laurence A, <i> et al.</i>: Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. <i>Eur J Immunol.</i> 2017; <b>47</b>(7): 1096–107. <a target=xrefwindow id=d88552e6665 href="http://www.ncbi.nlm.nih.gov/pubmed/28555727">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6668 href="http://dx.doi.org/10.1002/eji.201646680">Publisher Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727365803"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6677 class=n-a></a>Winthrop KL: The emerging safety profile of JAK inhibitors in rheumatic disease. <i>Nat Rev Rheumatol.</i> 2017; <b>13</b>(4): 234–43. <a target=xrefwindow id=d88552e6685 href="http://www.ncbi.nlm.nih.gov/pubmed/28250461">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6688 href="http://dx.doi.org/10.1038/nrrheum.2017.23">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727365803">F1000 Recommendation</a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d88552e6701 class=n-a></a>Archer TP, Moran GW, Ghosh S: Tofacitinib in ulcerative colitis. <i>Immunotherapy.</i> 2016; <b>8</b>(5): 495–502. <a target=xrefwindow id=d88552e6709 href="http://www.ncbi.nlm.nih.gov/pubmed/27140405">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6712 href="http://dx.doi.org/10.2217/imt-2015-0031">Publisher Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d88552e6722 class=n-a></a>Costa L, Del Puente A, Peluso R, <i> et al.</i>: Small molecule therapy for managing moderate to severe psoriatic arthritis. <i>Expert Opin Pharmacother.</i> 2017; <b>18</b>(15): 1557–67. <a target=xrefwindow id=d88552e6733 href="http://www.ncbi.nlm.nih.gov/pubmed/28891341">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6736 href="http://dx.doi.org/10.1080/14656566.2017.1378343">Publisher Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d88552e6745 class=n-a></a>Spoerl S, Mathew NR, Bscheider M, <i> et al.</i>: Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. <i>Blood.</i> 2014; <b>123</b>(24): 3832–42. <a target=xrefwindow id=d88552e6756 href="http://www.ncbi.nlm.nih.gov/pubmed/24711661">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6759 href="http://dx.doi.org/10.1182/blood-2013-12-543736">Publisher Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727835697"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6768 class=n-a></a>Richez C, Truchetet M, Kostine M, <i> et al.</i>: Efficacy of baricitinib in the treatment of rheumatoid arthritis. <i>Expert Opin Pharmacother.</i> 2017; <b>18</b>(13): 1399–407. <a target=xrefwindow id=d88552e6779 href="http://www.ncbi.nlm.nih.gov/pubmed/28737053">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6782 href="http://dx.doi.org/10.1080/14656566.2017.1359256">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727835697">F1000 Recommendation</a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726291749"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6795 class=n-a></a>Genovese MC, Yang F, Østergaard M, <i> et al.</i>: Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. <i>Ann Rheum Dis.</i> 2016; <b>75</b>(11): 1979–83. <a target=xrefwindow id=d88552e6806 href="http://www.ncbi.nlm.nih.gov/pubmed/27084959">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6809 href="http://dx.doi.org/10.1136/annrheumdis-2015-208901">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726291749">F1000 Recommendation</a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a name=d88552e6822 class=n-a></a>Haan C, Rolvering C, Raulf F, <i> et al.</i>: Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. <i>Chem Biol.</i> 2011; <b>18</b>(3): 314–23. <a target=xrefwindow id=d88552e6833 href="http://www.ncbi.nlm.nih.gov/pubmed/21439476">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6836 href="http://dx.doi.org/10.1016/j.chembiol.2011.01.012">Publisher Full Text </a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d88552e6845 class=n-a></a>Deshpande A, Reddy MM, Schade GO, <i> et al.</i>: Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. <i>Leukemia.</i> 2012; <b>26</b>(4): 708–15. <a target=xrefwindow id=d88552e6856 href="http://www.ncbi.nlm.nih.gov/pubmed/21926964">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6859 href="http://dx.doi.org/10.1038/leu.2011.255">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6863 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3974504">Free Full Text </a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d88552e6873 class=n-a></a>Hornakova T, Springuel L, Devreux J, <i> et al.</i>: Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. <i>Haematologica.</i> 2011; <b>96</b>(6): 845–53. <a target=xrefwindow id=d88552e6884 href="http://www.ncbi.nlm.nih.gov/pubmed/21393331">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6887 href="http://dx.doi.org/10.3324/haematol.2010.036350">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6891 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3105646">Free Full Text </a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d88552e6900 class=n-a></a>Zhang J, Adrián FJ, Jahnke W, <i> et al.</i>: Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. <i>Nature.</i> 2010; <b>463</b>(7280): 501–6. <a target=xrefwindow id=d88552e6911 href="http://www.ncbi.nlm.nih.gov/pubmed/20072125">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6914 href="http://dx.doi.org/10.1038/nature08675">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6918 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2901986">Free Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1007200"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6927 class=n-a></a>Ohren JF, Chen H, Pavlovsky A, <i> et al.</i>: Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. <i>Nat Struct Mol Biol.</i> 2004; <b>11</b>(12): 1192–7. <a target=xrefwindow id=d88552e6938 href="http://www.ncbi.nlm.nih.gov/pubmed/15543157">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6941 href="http://dx.doi.org/10.1038/nsmb859">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1007200">F1000 Recommendation</a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717952287"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e6954 class=n-a></a>Bandaranayake RM, Ungureanu D, Shan Y, <i> et al.</i>: Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. <i>Nat Struct Mol Biol.</i> 2012; <b>19</b>(8): 754–9. <a target=xrefwindow id=d88552e6965 href="http://www.ncbi.nlm.nih.gov/pubmed/22820988">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6968 href="http://dx.doi.org/10.1038/nsmb.2348">Publisher Full Text </a> | <a target=xrefwindow id=d88552e6972 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3414675">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717952287">F1000 Recommendation</a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a name=d88552e6985 class=n-a></a>Puleo DE, Kucera K, Hammarén HM, <i> et al.</i>: Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders. <i>ACS Med Chem Lett.</i> 2017; <b>8</b>(6): 618–21. <a target=xrefwindow id=d88552e6996 href="http://www.ncbi.nlm.nih.gov/pubmed/28626521">PubMed Abstract </a> | <a target=xrefwindow id=d88552e6999 href="http://dx.doi.org/10.1021/acsmedchemlett.7b00153">Publisher Full Text </a> | <a target=xrefwindow id=d88552e7003 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5467198">Free Full Text </a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a name=d88552e7012 class=n-a></a>Dusa A, Staerk J, Elliott J, <i> et al.</i>: Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. <i>J Biol Chem.</i> 2008; <b>283</b>(19): 12941–8. <a target=xrefwindow id=d88552e7023 href="http://www.ncbi.nlm.nih.gov/pubmed/18326042">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7026 href="http://dx.doi.org/10.1074/jbc.M709302200">Publisher Full Text </a></span></li><li><a name=ref-162 class=n-a></a><span class=label>162. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725607046"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e7036 class=n-a></a>Thomas S, Fisher KH, Snowden JA, <i> et al.</i>: Methotrexate Is a JAK/STAT Pathway Inhibitor. <i>PLoS One.</i> 2015; <b>10</b>(7): e0130078. <a target=xrefwindow id=d88552e7047 href="http://www.ncbi.nlm.nih.gov/pubmed/26131691">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7050 href="http://dx.doi.org/10.1371/journal.pone.0130078">Publisher Full Text </a> | <a target=xrefwindow id=d88552e7054 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4489434">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725607046">F1000 Recommendation</a></span></li><li><a name=ref-163 class=n-a></a><span class=label>163. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718321375"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e7067 class=n-a></a>Dussiot M, Maciel TT, Fricot A, <i> et al.</i>: An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. <i>Nat Med.</i> 2014; <b>20</b>(4): 398–407. <a target=xrefwindow id=d88552e7078 href="http://www.ncbi.nlm.nih.gov/pubmed/24658077">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7081 href="http://dx.doi.org/10.1038/nm.3468">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718321375">F1000 Recommendation</a></span></li><li><a name=ref-164 class=n-a></a><span class=label>164. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732417971"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e7094 class=n-a></a>McMullin MF, Harrison CN, Niederwieser D, <i> et al.</i>: The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. <i>Exp Hematol Oncol.</i> 2015; <b>4</b>: 26. <a target=xrefwindow id=d88552e7105 href="http://www.ncbi.nlm.nih.gov/pubmed/26380150">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7108 href="http://dx.doi.org/10.1186/s40164-015-0021-2">Publisher Full Text </a> | <a target=xrefwindow id=d88552e7112 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4570722">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732417971">F1000 Recommendation</a></span></li><li><a name=ref-165 class=n-a></a><span class=label>165. </span>&nbsp;<span class=citation><a name=d88552e7125 class=n-a></a>Ihle JN, Witthuhn BA, Quelle FW, <i> et al.</i>: Signaling through the hematopoietic cytokine receptors. <i>Annu Rev Immunol.</i> 1995; <b>13</b>: 369–98. <a target=xrefwindow id=d88552e7136 href="http://www.ncbi.nlm.nih.gov/pubmed/7612228">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7139 href="http://dx.doi.org/10.1146/annurev.iy.13.040195.002101">Publisher Full Text </a></span></li><li><a name=ref-166 class=n-a></a><span class=label>166. </span>&nbsp;<span class=citation><a name=d88552e7148 class=n-a></a>Lai P, Rosa DA, Magdy Ali A, <i> et al.</i>: A STAT inhibitor patent review: progress since 2011. <i>Expert Opin Ther Pat.</i> 2015; <b>25</b>(12): 1397–421. <a target=xrefwindow id=d88552e7159 href="http://www.ncbi.nlm.nih.gov/pubmed/26394986">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7162 href="http://dx.doi.org/10.1517/13543776.2015.1086749">Publisher Full Text </a></span></li><li><a name=ref-167 class=n-a></a><span class=label>167. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718179867"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e7171 class=n-a></a>Bartalucci N, Tozzi L, Bogani C, <i> et al.</i>: Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. <i>J Cell Mol Med.</i> 2013; <b>17</b>(11): 1385–96. <a target=xrefwindow id=d88552e7182 href="http://www.ncbi.nlm.nih.gov/pubmed/24237791">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7185 href="http://dx.doi.org/10.1111/jcmm.12162">Publisher Full Text </a> | <a target=xrefwindow id=d88552e7189 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4117551">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718179867">F1000 Recommendation</a></span></li><li><a name=ref-168 class=n-a></a><span class=label>168. </span>&nbsp;<span class=citation><a name=d88552e7203 class=n-a></a>Choong ML, Pecquet C, Pendharkar V, <i> et al.</i>: Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. <i>J Cell Mol Med.</i> 2013; <b>17</b>(11): 1397–409. <a target=xrefwindow id=d88552e7214 href="http://www.ncbi.nlm.nih.gov/pubmed/24251790">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7217 href="http://dx.doi.org/10.1111/jcmm.12156">Publisher Full Text </a> | <a target=xrefwindow id=d88552e7221 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4117552">Free Full Text </a></span></li><li><a name=ref-169 class=n-a></a><span class=label>169. </span>&nbsp;<span class=citation><a name=d88552e7230 class=n-a></a>Marubayashi S, Koppikar P, Taldone T, <i> et al.</i>: HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. <i>J Clin Invest.</i> 2010; <b>120</b>(10): 3578–93. <a target=xrefwindow id=d88552e7241 href="http://www.ncbi.nlm.nih.gov/pubmed/20852385">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7244 href="http://dx.doi.org/10.1172/JCI42442">Publisher Full Text </a> | <a target=xrefwindow id=d88552e7248 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2947224">Free Full Text </a></span></li><li><a name=ref-170 class=n-a></a><span class=label>170. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727086783"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e7257 class=n-a></a>Mascarenhas J, Sandy L, Lu M, <i> et al.</i>: A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). <i>Leuk Res.</i> 2017; <b>53</b>: 13–9. <a target=xrefwindow id=d88552e7268 href="http://www.ncbi.nlm.nih.gov/pubmed/27930945">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7271 href="http://dx.doi.org/10.1016/j.leukres.2016.11.015">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727086783">F1000 Recommendation</a></span></li><li><a name=ref-171 class=n-a></a><span class=label>171. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732019716"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e7284 class=n-a></a>Hobbs GS, Hanasoge Somasundara AV, Kleppe M, <i> et al.</i>: Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. <i>Haematologica.</i> 2018; <b>103</b>(1): e5–e9. <a target=xrefwindow id=d88552e7295 href="http://www.ncbi.nlm.nih.gov/pubmed/29051283">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7298 href="http://dx.doi.org/10.3324/haematol.2017.177600">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732019716">F1000 Recommendation</a></span></li><li><a name=ref-172 class=n-a></a><span class=label>172. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727501146"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e7311 class=n-a></a>Bjørn ME, Hasselbalch HC: Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. <i>Expert Rev Hematol.</i> 2017; <b>10</b>(5): 393–404. <a target=xrefwindow id=d88552e7319 href="http://www.ncbi.nlm.nih.gov/pubmed/28402197">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7322 href="http://dx.doi.org/10.1080/17474086.2017.1284583">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727501146">F1000 Recommendation</a></span></li><li><a name=ref-173 class=n-a></a><span class=label>173. </span>&nbsp;<span class=citation><a name=d88552e7335 class=n-a></a>Duffield JS, Lupher ML Jr: PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. <i>Drug News Perspect.</i> 2010; <b>23</b>(5): 305–15. <a target=xrefwindow id=d88552e7343 href="http://www.ncbi.nlm.nih.gov/pubmed/20603654">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7346 href="http://dx.doi.org/10.1358/dnp.2010.23.5.1444206">Publisher Full Text </a></span></li><li><a name=ref-174 class=n-a></a><span class=label>174. </span>&nbsp;<span class=citation><a name=d88552e7356 class=n-a></a>Verstovsek S, Manshouri T, Pilling D, <i> et al.</i>: Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. <i>J Exp Med.</i> 2016; <b>213</b>(9): 1723–40. <a target=xrefwindow id=d88552e7367 href="http://www.ncbi.nlm.nih.gov/pubmed/27481130">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7370 href="http://dx.doi.org/10.1084/jem.20160283">Publisher Full Text </a> | <a target=xrefwindow id=d88552e7374 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4995084">Free Full Text </a></span></li><li><a name=ref-175 class=n-a></a><span class=label>175. </span>&nbsp;<span class=citation><a name=d88552e7383 class=n-a></a>Stein BL, Swords R, Hochhaus A, <i> et al.</i>: Novel myelofibrosis treatment strategies: potential partners for combination therapies. <i>Leukemia.</i> 2014; <b>28</b>(11): 2139–47. <a target=xrefwindow id=d88552e7394 href="http://www.ncbi.nlm.nih.gov/pubmed/24888274">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7397 href="http://dx.doi.org/10.1038/leu.2014.176">Publisher Full Text </a></span></li><li><a name=ref-176 class=n-a></a><span class=label>176. </span>&nbsp;<span class=citation><a name=d88552e7406 class=n-a></a>Sasaki K, Gotlib JR, Mesa RA, <i> et al.</i>: Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. <i>Leuk Lymphoma.</i> 2015; <b>56</b>(7): 2092–7. <a target=xrefwindow id=d88552e7417 href="http://www.ncbi.nlm.nih.gov/pubmed/25641433">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7420 href="http://dx.doi.org/10.3109/10428194.2014.984703">Publisher Full Text </a> | <a target=xrefwindow id=d88552e7424 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4919663">Free Full Text </a></span></li><li><a name=ref-177 class=n-a></a><span class=label>177. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727567167"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e7433 class=n-a></a>Schneider RK, Mullally A, Dugourd A, <i> et al.</i>: Gli1<sup>+</sup> Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. <i>Cell Stem Cell.</i> 2017; <b>20</b>(6): 785–800.e8. <a target=xrefwindow id=d88552e7447 href="http://www.ncbi.nlm.nih.gov/pubmed/28457748">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7451 href="http://dx.doi.org/10.1016/j.stem.2017.03.008">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727567167">F1000 Recommendation</a></span></li><li><a name=ref-178 class=n-a></a><span class=label>178. </span>&nbsp;<span class=citation><a name=d88552e7464 class=n-a></a>Liu F, Zhao X, Perna F, <i> et al.</i>: JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. <i>Cancer Cell.</i> 2011; <b>19</b>(2): 283–94. <a target=xrefwindow id=d88552e7475 href="http://www.ncbi.nlm.nih.gov/pubmed/21316606">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7478 href="http://dx.doi.org/10.1016/j.ccr.2010.12.020">Publisher Full Text </a> | <a target=xrefwindow id=d88552e7482 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4687747">Free Full Text </a></span></li><li><a name=ref-179 class=n-a></a><span class=label>179. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1166393"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e7491 class=n-a></a>Dawson MA, Bannister AJ, Göttgens B, <i> et al.</i>: JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. <i>Nature.</i> 2009; <b>461</b>(7265): 819–22. <a target=xrefwindow id=d88552e7502 href="http://www.ncbi.nlm.nih.gov/pubmed/19783980">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7505 href="http://dx.doi.org/10.1038/nature08448">Publisher Full Text </a> | <a target=xrefwindow id=d88552e7509 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3785147">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1166393">F1000 Recommendation</a></span></li><li><a name=ref-180 class=n-a></a><span class=label>180. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725757463"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e7523 class=n-a></a>Badar T, Kantarjian HM, Ravandi F, <i> et al.</i>: Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. <i>Leuk Res.</i> 2015; <b>39</b>(9): 950–6. <a target=xrefwindow id=d88552e7534 href="http://www.ncbi.nlm.nih.gov/pubmed/26183878">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7537 href="http://dx.doi.org/10.1016/j.leukres.2015.06.001">Publisher Full Text </a> | <a target=xrefwindow id=d88552e7541 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4546869">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725757463">F1000 Recommendation</a></span></li><li><a name=ref-181 class=n-a></a><span class=label>181. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1115745"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d88552e7554 class=n-a></a>Quintás-Cardama A, Tong W, Kantarjian H, <i> et al.</i>: A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. <i>Leukemia.</i> 2008; <b>22</b>(5): 965–70. <a target=xrefwindow id=d88552e7565 href="http://www.ncbi.nlm.nih.gov/pubmed/18385750">PubMed Abstract </a> | <a target=xrefwindow id=d88552e7568 href="http://dx.doi.org/10.1038/leu.2008.91">Publisher Full Text </a> | <a target=xrefwindow id=d88552e7572 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4369783">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1115745">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 17 Jan 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-82/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-82/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> INSERM UMR 1170, Gustave Roussy, Villejuif, France<br/> <sup>2</sup> Universit&eacute; Paris-Saclay, UMR1170, Gustave Roussy, Villejuif, France<br/> <sup>3</sup> UMR 1170, Gustave Roussy, Villejuif, France<br/> <sup>4</sup> Signal Transduction &amp; Molecular Hematology Unit, Ludwig Institute for Cancer Research, Brussels, Belgium<br/> <sup>5</sup> de Duve Institute, Universit&eacute; catholique de Louvain, Brussels, Belgium<br/> <sup>6</sup> Institut National de la Transfusion Sanguine, Paris, France<br/> <p> <div class=margin-bottom> William Vainchenker <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Emilie Leroy <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Laure Gilles <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Caroline Marty <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Isabelle Plo <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Stefan N. Constantinescu <br/> <span>Roles: </span> Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-82/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 17 Jan 2018, 7:82 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.13167.1">https://doi.org/10.12688/f1000research.13167.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Vainchenker W <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=14282 data-id=13167 data-downloads="" data-views="" data-scholar="10.12688/f1000research.13167.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-82/v1/pdf?article_uuid=1e9edc68-e339-46e0-83ab-1355fe0b3138" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.13167.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Vainchenker W, Leroy E, Gilles L <em>et al.</em> JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):82 (<a href="https://doi.org/10.12688/f1000research.13167.1" target=_blank>https://doi.org/10.12688/f1000research.13167.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=13167 id=mobile-track-article-signin-13167 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/13167?target=/articles/7-82/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=14282 /> <input name=articleId type=hidden value=13167 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Ann Mullally</strong>, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Srdan Verstovsek</strong>, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 17 Jan 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-82/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-82/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=8359-29676></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=29675-29677></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-82/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>17 Jan 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Ann Mullally</strong>, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Srdan Verstovsek</strong>, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-82/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-82/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "JAK inhibitors for the treatment of myeloproliferative...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-82/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-82/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-82/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Vainchenker W et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-82/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-82",
            templates : {
                twitter : "JAK inhibitors for the treatment of myeloproliferative neoplasms.... Vainchenker W et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-82/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/13167/14282")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "14282");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "29676": 0,
                           "29677": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "4ee9a23f-2ef9-45b0-8838-874d40f711d3";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-82.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-82.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-82.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-82.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-82.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>